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Despite significant advances in surgery and biology, cancer remains a major health problem 
because of tumour cell metastasis and resistance to chemotherapeutic drugs. Cisplatin has 
been described as ‘the penicillin’ of cancer and was the first platinum-based chemotherapeutic 
drug developed for cancer treatment. However, it has the unfortunate downside of 
chemoresistance, thus limiting its applicability to the treatment of the more responsive 
hormone-negative, rather than hormone-positive, metastatic breast cancer. 
Tissue transglutaminase 2 (TG2), a multifunctional Ca2+ enzyme, belongs to a family of related 
genes involved in various cellular processes such as the cell cycle, adhesion, protein 
crosslinking, endocytosis and apoptosis. It is overexpressed in cancer and chemoresistant 
cells and implicated in encouraging resistance to anti-cancer drugs. The enzyme exists in 
structurally different isoforms, which are thought to have opposing functions. The full length 
TG2-L supports cell survival; while the truncated TG2-S form promotes cell death. However, 
the mechanism has not been investigated in breast cancer. 
The effect of altering the expression of TG2-L and TG2-S isoforms was investigated in 
cisplatin-sensitive and cisplatin-resistant hormone-positive MCF-7 breast cancer cells. The 
cells were treated with non-toxic doses of retinoic acid up to 72 hours in order to raise TG2 
expression, while inhibition of TG2 was achieved with cystamine and specific anti-TG2 
silencing RNA (siRNA). MTT assay measured cellular viability; flow cytometry measured levels 
of apoptosis and necrosis, and Western blot analysis measured TG2 isoform expression. 
The results generated from this study reveal for the first time that retinoic acid treatment of 
both wild type and cisplatin-resistant cell lines, induced overexpression of TG2-L but had little 
or no effect on TG-S expression, promoting cell survival and increasing cisplatin 
chemoresistance in all cases. Conversely, TG2 inhibition with cystamine and siRNA treatment 
selectively suppressed TG2-L expression (with little effect on TG2-S expression) and reduced 
cisplatin resistance to basal control levels without affecting cell viability, in all cells tested.  
Collectively, the results suggest that targeting TG2-L by controlling levels of dietary retinoid 
consumption, could be a potential therapeutic tool in combating cisplatin resistance in 
hormone-positive breast cancer patients where, currently,  rapid induction of resistance is a 
barrier to effective treatment and cisplatin therapy.  
Keywords: Retinoic acid, TG2, Cisplatin, Cancer. 
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Chapter 1: Introduction 
 
1.0 Cancer 
 
Cancer is a prominent multifactorial disease and amongst one of the leading causes of death 
worldwide. These group of diseases arise from genetic and epigenetic alterations of healthy 
cells, leading to irregular proliferation (Senthebane et al., 2018).  The process begins when 
healthy cells change from their normal state to a hyper-proliferative state, exhibiting 
characteristic features: an unlimited ability for growth, disregard to programmed cell death, 
activating invasion and metastasis (figure 1.10). These changes are often caused by genetic 
mutations that either deactivate tumour suppressor genes or activate oncogenes (Coleman et 
al., 2008).  A vital factor in the development of cancer is the inactivation of programmed cell 
death (Brown and Attardi, 2005) and defective apoptotic signalling, which results in several 
human diseases, including cancer (Johnson, 2013).  
1.1 Apoptosis 
 
Apoptosis is a highly regulated and conserved form of cell death and plays a considerable 
physiological aspect in embryonic development as well as in ageing. Also, proliferation and 
cell death must be controlled to maintain tissue homeostasis (Elmore, S., 2007). Cancer is an 
example where the normal machinery of the cell cycle regulation is defective, with either 
decreased removal of abnormal cells and/or an overproliferation of cells (King and 
Cidlowski,1998). Apoptosis is activated by a variety of stimuli which include: oxidative stress, 
irradiation, chemotherapeutic agents and endoplasmic reticulum stress. The caspase family 
of cysteine proteases act as effector molecules in apoptosis; they are initially synthesised as 
inactive proenzymes but on activation can cleave various molecules in the nucleus and 
cytoplasm, which eventually leads to the morphological features seen in apoptotic cell death 
such as DNA fragmentation, nucleus shrinkage and loss of cell shape (Fulde et al., 2009). 
 2 
 
Caspases are activated by the tumour necrosis factor (TNF) or TNF-related apoptosis-
inducing ligand (TRAIL), which results in receptor aggregation and the recruitment of fas 
associated death domain (FADD) and finally pro-caspase-8. A death-inducing signal complex 
is formed with the activation of caspase-8 and the resultant initiation of apoptosis by directly 
cleaving downstream effector caspases. Another mechanism by which caspases are activated 
is through the mitochondria pathway initiated by the apoptosis-inducing factor (AIF), 
cytochrome c, second mitochondria-derived activator of caspases (SMAC) and Diablo IAP-
Binding Mitochondrial Protein direct (DIABLO) homolog protein. When cytochrome c is 
released into the cytosol by cellular stress, it results in the formation of a cytochrome c/ 
apoptotic protease activating factor 1 /caspase 9 apoptosome complex with the resultant 
activation of caspases. Activation of caspases has to be regulated because of the detrimental 
effect it has on cell survival if inappropriately activated (Fulde et al., 2009). 
The Bcl-2 (B-cell lymphoma 2) gene family of proteins, regulates proteins that either inhibit or 
promotes apoptosis. The pro-apoptotic proteins include Bcl-2 homologous antagonist/killer 
(Bak), apoptosis regulator (Bax), Bcl-2 associated agonist of cell death (Bad), and B-cell 
lymphoma short-form (Bcl-xs), while Bcl-2 and B-cell lymphoma long-form (Bcl-xL) are anti-
apoptotic. Overexpression of anti-apoptotic and underexpression of pro-apoptotic proteins 
result in reduced cell death, which is synonymous with cancers. Bcl-2 is expressed in 
approximately 80% of breast cancers and correlates with the expression of progesterone and 
oestrogen receptors (Cory et al., 2003). 
Other proteins that inhibit apoptosis include, X-linked inhibitor of apoptosis protein (XIAP), 
cellular inhibitor of apoptosis protein 1(cIAP1), and cellular inhibitor of apoptosis protein 2 
(cIAP2) which prevent apoptosis by inhibiting caspases (Parton et al., 2001).  
Indeed both increased and defective apoptosis have different pathological outcomes, while 
increased apoptosis causes atrophy, defective apoptosis results in unrestrained cell 
proliferation, such as cancer (Favaloro et al., 2012). 
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Figure 1.1: Schematic diagram showing apoptosis in the healthy breast cell and defective 
apoptosis in the breast cancer cell 
 
1.2 Human breast carcinoma 
 
Amongst women worldwide, breast cancer is the most common and principal cause of cancer-
related deaths after lung cancer and the 2nd cause of death in the UK, according to the 2016 
cancer statistics. The human breast is characterised by connective tissues, fat, glandular 
tissues and is divided into lobes with a web of ducts spreading to the nipples from the lobes 
(see figure 1.1). Breast cancers consist of two main types: in situ and invasive carcinoma. In 
situ breast carcinoma arises from either the lobular or ductal epithelium and is confined to 
these spaces without invading the basement membrane, which constitutes the boundaries of 
the mammary epithelium. When the malignancy from the lobes or ducts extends past the 
basement membrane, such malignancy is seen as invasive carcinoma. The main cause of 
death from breast cancer is mainly due to metastasis of the invasive disease (Richie and 
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Swanson, 2003), and approximately 10% of diagnosed breast cancer is of the invasive lobular 
type (Cancer Research UK). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Anatomy of the human breast.  
Composition of the human breast showing the lobes, ducts and fatty tissues. 
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Table 1.1 shows a list of the different types of breast cancer depending on the specific cell 
type of origin. 
 
Table 1.1: Breast cancer types (Cancer Research UK) 
 Breast cancer type Cell type of origin 
1. Invasive breast cancer  Lobular cells 
2. Invasive lobular breast cancer Lobular cells 
3.  Triple-negative breast cancer Cells without oestrogen, progesterone or 
HER2+ receptors. 
4. Inflammatory breast cancer Cells lining the lymph channel 
5. Angiosarcoma of the breast Cells that line the blood or lymphatic 
vessels. 
6. Ductal carcinoma in situ (DCIS) Cells that line the ducts of the breast tissue 
7. Lobular carcinoma in situ (LCIS) Cells inside the breast lobules 
8 Male breast cancer Cells that line up the ducts of the breast 
tissue 
10. Paget’s disease of the breast 
 
Nipple or areola 
 
The risk factors for developing breast cancer are numerous, and these include gender, age, 
genetics, use of hormonal replacement therapy (HRT), breast density and family history of 
breast cancer. Other risk factors include exposure to radiation treatment, race and ethnicity, 
obesity, use of oral contraceptives, smoking, alcohol and lack of breastfeeding. Statistics 
available predict 1 out of 7 women will have breast cancer during their lifetime; out of this 
number, 23% of these cases would have been preventable (Cancer Research UK).  
In humans, the hormones oestrogen, progesterone and the human epidermal growth factor 
type 2 are needed for healthy breast cells to grow and divide and also some cancer cells. 
Receptors for these hormones are found in or on cells and attach to the hormones and serve 
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as biomarkers to detect the type of breast cancers, and are used for breast cancer testing 
(Conger et al., 2016). Table 1.2 characterises breast cancer based on their receptor status. 
Oestrogen-positive (ER+ve) cancer grow in response to the hormone oestrogen; HER-2 
positive tumours overexpress the HER-2 receptor; and triple-negative breast cancer does not 
express surface receptors for the ligands of HER2 or the hormones oestrogen or progesterone 
(Duffy, 2006).  
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Table 1.2: Types of breast cancer 
 
 
Oestrogen exists commonly in three forms: oestrone (E1), 17β-oestradiol (E2), and oestriol 
(E3). In premenopausal women, E2 is the predominant oestrogen produced while E3 is 
produced after menopause (Lipovka et al.,2016). Oestrogen promotes the growth of sexual 
organ maturation and secondary sexual characteristics in females and is synthesised in the 
ovaries, mesenchymal cells of the adipose tissues of osteoblasts, chondrocytes, vascular 
endothelium and the breasts (Simpson, 2003). Both oestrogen(E2) and oestrogen receptors 
(ER) have been implicated in the progression of breast cancer (Saha and Vadlamudi., 2012). 
Figure 1.3 shows the involvement of E2 and ER in tumorigenesis and metastasis. 
Hormone Type of breast cancer Receptor 
Oestrogen Oestrogen-positive (ER+) Oestrogen receptor (ER) 
Progesterone  Progesterone-positive (PR+) Progesterone receptor (PR), 
Human epidermal growth 
factor type 2 
HER2 +ve The human epidermal 
growth factor receptor-2 
(HER2). 
Absence of Oestrogen, 
Progesterone and Human 
epidermal growth factor type 
2 
Triple-negative cancer No receptor expressed  
Presence of Oestrogen, 
Progesterone and Human 
epidermal growth factor type 
2 
Triple positive cancer                                             All receptors expressed 
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Figure 1.3: Schematic representation of oestrogen regulation of both tumorigenesis and 
metastasis 
 
1. 2.1 Oestrogen receptor-positive breast cancer  
 
The physiological functions of oestrogen are facilitated mainly via the oestrogen receptors 
(ER), which has two subtypes oestrogen receptor alpha (Erα) and oestrogen receptor beta 
(Erβ) with distinct characteristics and expression patterns. ERα is expressed more 
ubiquitously throughout the body, whereas the pattern of ERβ is limited to the ovary, thymus 
and testis. Both ERα and ERβ receptors are found in the normal breast, expression of  ERβ 
seems to be the receptor widespread in mammary tissues (Speirs et al., 2002) and expressed 
in epithelial and stromal cells while ERα is expressed in a subcategory of epithelial cells (Li et 
al., 2010). 
Both isoforms are essential because they control multiple physiological processes, such as 
cellular growth, differentiation, and function of the reproductive mammary gland. It has also 
been implicated in several diseases, especially breast cancer (Duffy, 2006) owing to some 
signalling pathways it controls which worsen the progression of ER-positive tumours (Lipovka 
and Konhilas, 2016).  
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The receptors are over-expressed in around 70% of breast cancer cases, and evidence 
suggests that binding of oestrogen to the ER receptors encourages the propagation of 
mammary cells, resulting in increased DNA replication and cell division. The pathology also 
involves the interruption of the normal cell cycle, DNA repair and apoptosis and, consequently 
leads to tumour formation (Deroo and Korach, 2005).  
1.2.2 MCF-7 breast cancer cell line (hormone positive) 
 
The human MCF-7 breast cancer cell line, which expresses the oestrogen receptor, was 
obtained from a patient who had metastatic disease in the 1970s, and it has been the standard 
system for studying oestrogen-positive breast cancer (Simstein et al., 2003). Since its 
isolation, the MCF-7 breast cancer cell line has been extensively studied, and results obtained 
have contributed immensely towards breast cancer research and the improvement of the 
patient treatment outcome (Lee et al., 2015).  
1.2.3 Triple-negative breast cancer (TNBC) 
 
Triple-negative breast cancer is characterised by the absence of oestrogen receptors, HER2 
and progesterone receptor, and is typically a basal-like breast cancer (Foulkes et al., 2010). 
TNBC occurs in about 10–20% of breast carcinomas and mostly affects younger women, 
women with high parity, high body mass index, and lack of breastfeeding, those with a 
mutation in the BRCA1 gene and specifically those of the Hispanic and African – American 
race (Dawood et al., 2010). Owing to the absence of receptors (ER.PR and HER2), TNBC is 
unresponsive to hormonal and HER2 targeted treatments, and cytotoxic therapies have been 
the choice for chemotherapy. Research such as identifying MAPK/ERK pathway inhibitors, 
Phosphoinositide 3-kinases (PI3Ks) inhibitors, Heat shock protein (HSP-90) inhibitors, 
programmed death 1 (PD-1) inhibitors and histone deacetylase inhibitors. These are some 
agents being considered/currently under investigation clinically against this triple-negative 
breast cancer (Abrahamson et al., 2014) 
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1.2.4 HCC 1806 breast cancer cell line (hormone negative) 
 
The human HCC 1806 breast cancer cell line (TNBC) is categorised by the loss or reduced 
expression of the progesterone receptor, oestrogen receptor and HER2 protein. Triple-
negative breast cancer type is typically aggressive owing to its invasive nature, the lack of 
receptors on the tumour makes conventional breast cancer treatments that target the 
receptors, hormone therapy ineffective (Rorie et al., 2012). There has been slight progress in 
the formation of drug treatments to target this breast cancer subtype, though no precise 
therapies exist presently for TNBC cytotoxic chemotherapy; research is currently ongoing to 
identify possible targets for improved therapy (Al-Bahlani et al.,2018). 
1.2.5 Breast cancer treatments 
 
Six types of breast cancer treatments are currently available: chemotherapy, surgery, radiation 
therapy, hormone therapy, targeted therapy and immunotherapy. Chemotherapy treatment 
depends on the type of breast cancer involved; oestrogen-positive breast cancers require 
treatments that prevent the hormones from binding to the receptors. An example is tamoxifen 
used mainly in postmenopausal women, and this drug inhibits proliferation activities of 
oestrogen by binding to the oestrogen receptors. Targeted cancer therapy is used to treat 
HER2+ve breast cancer. Trastuzumab (monoclonal antibody), is an example of a 
chemotherapeutic drug used to treat  HER2 +ve  breast cancers, the drug attaches to and 
interferes with the HER2 receptor proteins on or in cancer cells. Drugs that target BRCA 
(breast cancer gene) DNA repair gene mutation are used to treat triple-negative cancers 
(Cancer Research UK). 
1.2.6 Regulation of apoptosis in the mammary gland 
 
Development of the breast is in two physiological stages, puberty and pregnancy, where there 
are noticeable changes in differentiation and proliferation. Before the onset of pregnancy, 
terminal cells of the developing mammary ducts remain mitotically quiet, but during pregnancy, 
there is a rapid proliferation including lobular alveoli growth and ductal branching (Javed and 
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Lteif, 2013). Then, after the end of lactation, restructuring and apoptosis occur, returning the 
breast to its primary structure. When pregnancy does not happen, the cells continue resting 
while the menstrual cycle is active until menopause, when apoptosis occurs in the terminal 
duct and lobular duct. For healthy development and homeostasis, a balance exists between 
differentiation, proliferation and cell death. Thus, variations that could cause the increase of 
cellular proliferation and decrease of apoptosis might allow the build-up of mutations resulting 
in breast cancer (Green and Streuli, 2004; Javed and Lteif, 2013). Variation of the B-cell 
lymphoma 2  family of apoptotic regulatory proteins occurs partly due to the influence of the 
hormone oestrogens and progesterone. Also, defective cellular processes with functions to 
detect damaged DNA contributes to the acquisition of cancer (Parton et al., 2001). 
Cells respond to stress either in the activation of cell survival pathways or through cell death 
with the elimination of the damaged cell. To a large extent, whether cells display a protective 
or destructive response depends mostly to the duration and nature of the stress and cell type 
involved. Also, there is evidence for cross-talk between the two cellular responses that finally 
decides the outcome of the stressed cell. The mechanism of cell death, whether it occurs by 
apoptosis, necrosis, pyroptosis or autophagy hinges on the cells ability to deal with the stress 
and also on several exogenous factors (Fulde et al., 2009). 
Apoptosis is a form of organised/programmed cell death. This form of cell death is 
accompanied by cell rounding up, pyknosis (reduction of cellular volume), chromatin 
condensation, karyorrhexis (nuclear fragmentation), plasma membrane blebbing but the 
integrity is maintained until phagocytes engulf the cell (Baehrecke, 2002; Kroemer et al., 
2009). 
Necrosis is not an organised programmed death but a rupture of the plasma membrane and 
loss of cellular contents. This form of cell death is characterised by oncosis (gain in cell 
volume), swelling of organelles and finally cell rupture (Kroemer et al., 2009). Necrosis is seen 
as a form of uncontrolled cell death, but accumulating evidence suggests a set of signalling 
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pathways may regulate it. For example, Toll-like receptors (TLR3 and TLR4) and death 
domain receptors have been observed to provoke necrosis (Festjens et al., 2006). 
Autophagy is described as a ‘self-eating’ form of cell death, and the process is characterised 
by the vesicular sequestration and degradation of organelles. It is a regulated, orderly 
mechanism that eliminates dysfunctional or unnecessary cellular components and allows for 
recycling (Kroemer et al., 2009). 
1.3 Transglutaminases 
 
Transglutaminases consist of a nine-member family of both intracellular and extracellular 
enzymes, which are Ca2+-dependent and catalyse the posttranslational modification of 
proteins. These family members are extensively distributed in a wide range of organisms from 
bacteria to plants and animals (Bergamin et al., 2007; Siegel and Khosla 2007). As enzymes, 
they exert their function through the modification of protein targets, and themselves undergo 
several post-translational modifications including nitrosylations, phosphorylation, proteolytic 
cleavages and fatty acylation reactions (Esposito and Caputo, 2005).  
The transglutaminase family (Table 1.3) is made up of transglutaminase 1 (TG1), 
transglutaminase 3 (TG3) and transglutaminase 5 (TG5) are intracellular proteins and 
expressed in the epithelial tissues. Tissue transglutaminase 2 (TG2) is found in both 
intracellular and extracellular locations and expressed in a diverse range of body tissues; 
transglutaminase 4 (TG4) is expressed in the prostate gland and factor XIII which is expressed 
in the blood. The other members,  transglutaminase 6 (TG6) and transglutaminase 7 (TG7) 
are ubiquitous, while the enzymatically inactive band 4.2 is an erythrocyte membrane-
associated protein that maintains the integrity of the erythrocyte membrane (Esposito and 
Caputo,2005; Siegel and Khosta, 2007).  
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Table 1.3: The nomenclature and distribution of transglutaminases family members (Siegel 
and Khosta, 2007). 
 
Transglutaminases    Alternative names  Tissue Location 
Transglutaminase 1 TG1, TGK, keratinocyte 
TG, particulate TG 
Epithelia Cytosolic, 
membrane 
 
Transglutaminase 2            tTG, TGC, TG2, Tgase 
 
Ubiquitous Cytosolic, nuclear, 
 mitochondria, 
extracellular 
Transglutaminase 3 Callus TG, Epidermal TG, 
hair follicles, bovine snout 
TG   
Epithelia Cytosolic 
Transglutaminase 4 Type 4 TG/ prostrate TG. Prostate Extracellular 
Transglutaminase 5 Type 5 TG, TG5, TGX. Epithelia Cytosolic 
Transglutaminase 6 TG6. type 6 TG and TGY Ubiquitous Extracellular 
Transglutaminase 7 Type 7 TG, TG7/TGZ Ubiquitous Membrane 
 
Transglutaminase factor VIII                           Plasma TG, factor XIII A, 
fibrin stabilising factor.  
Blood                                              
                                 
plasma, 
                                          
platelets 
Extracellular
 
Band 4.2                         B4.2 Erythrocytes Membrane 
 
 
1.4 Tissue transglutaminase 2 (TG2) 
 
Discovered in 1957 by Waesch and Heinrich, TG2 was first detected in mammalian liver 
homogenates, and It is the most studied and biologically characterised member of the 
transglutaminase protein family (Thomazy and Fesus, 1989). TG2 is also known as tTG, type 
II transglutaminase or ‘liver transglutaminase’ because of its high abundance in the liver. With 
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a molecular weight of 75 kD, it consists of 687 amino acids and is involved in several cellular 
processes, including the cell cycle, endocytosis, protein crosslinking, cellular adhesion and 
apoptosis. The protein has been linked with several diseases such as coeliac sprue, 
Alzheimer’s disease, Huntington's disease (Hoffner and Djian, 2005), breast cancer (Herman 
et al., 2006), pancreatic cancer (Akar et al., 2007), colorectal cancer (Miyoshi et al., 2010) and 
several other cancer types (Mangala and Mehta, 2005; Siegel and Khosta, 2007), where it is 
typically overexpressed (Mehta, 1999).  
TG2, like other family members, is involved in posttranslational modification of proteins, which 
occurs at the amide moiety of glutamyl-side chains of protein substrates (Bergamin et al., 
2007), sometimes introducing isopeptide bonds within and/or between the glutamyl and lysine 
polypeptide chains (Chen and Mehta, 1999). Such bonds have tremendous physiological 
significance because of their stable and resilient nature to mechanical and proteolytic 
breakdown and can only be broken through total proteolytic degradation such as lysosomal 
proteolysis of the proteins involved (Chen and Mehta, 1999). 
1.5 Structure of TG2 and the conformational control of TG2 activity 
 
Human TG2 displays the four-domain structure peculiar to other transglutaminases (figure 
1.4a) which includes an N-terminal β-sandwich domain that consists of 130-140 amino acids 
and folds into β-strands and an α-helix (Hitomi et al., 2016).  
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Figure 1.4: (a) Crystal Structure of tissue transglutaminase 2 (Laszlo and Piacentini, 2002) and 
schematic representation (b) of the four different protein domains and the number of amino 
acids.  
 
The first domain, the β sandwich domain, is made up of 139 amino acids, the catalytic core 
domain contains a catalytic. A catalytic core is made up of a set of three amino acids found 
near the active site, and for TG2, it consists of the triad Cys-277, His-335, and Asp-358, 
arranged in a charge-relay system.  The catalytic core is involved in acyl transfer and catalytic 
reactions while the other two domains are the β-barrel domains. These domains have binding 
sites for several cellular compounds, e.g., fibronectin and integrin-binding sites are located on 
the N-terminal β-sandwich, and a phospholipase C binding site is found in the C-terminal (as 
reviewed by Onyekachi and Coussons 2013).   
The highly preserved catalytic triad of Cys277-His335-Asp358 shared by other enzymatically 
active members is involved in catalysing transamidation, transamination and protein cross-
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linking reactions, but unlike other transglutaminases, TG2 requires Ca2+ for its activation. Upon 
activation by Ca2+, cysteine 277 becomes extremely reactive and mediates the catalytic step 
towards peptidyl-glutamyl substrate(s). This reaction forms a thioester intermediate that is 
stabilised by interaction with an additional essential amino acid, tryptophan residue (Bergamini 
et al., 2011). 
The availability of Ca2+ ions in the cellular milieu controls the activity and the conformational 
state of TG2. Two major types of structural conformation exist (fig 1.5) based on which cofactor 
is bound to the catalytic core. A ‘closed’ or ‘compact’ conformation is formed when the 
guanotide molecules (GTP) bind to it, and in this state, the β-barrel domain folds over the 
catalytic triad and access to Cys 277 is obstructed by the C-terminal β-barrels. Cys 277 is a 
significant regulator of the activity of the enzyme, and in this conformation, it is inactive. Liu et 
al.,(2002), put forth the hypothesis that when GTP/GDP binds to TG2, it stabilises or secures 
the conformation, preventing substances from accessing the catalytic site. However, when 
bound by Ca2+ ions, the β-barrel shifts away from the catalytic triad allowing substances into 
the active site and forming the ‘open’ or ‘active’ conformation of the enzyme. In summary, TG2 
enzyme activity depends on the conformation of the protein, the presence of either calcium 
ions or nucleotides (GTP or GTP). This activity is also dependent on the spliced state of the 
gene product (section 1.10). 
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Figure 1.5: Crystal structure of the closed and open conformation of TG2 (Han et al.,2010) and 
a schematic representation showing the closed (a) and open (b) form based on the availability 
of either calcium of GTP and schematic representation (c) of the crystal form.  
 
There is a competition between the guanotides and Ca2+ to change the conformation to either 
the ‘closed’ or the ‘open’ state. Intracellular TG2 is assumed to be in the ‘closed’ state because 
of the high GDP/GTP levels with only a small proportion being in the open state. Conversely, 
extracellular TG2 is presumed to be in the ‘open’ state because of the low GTP and high Ca2+ 
concentrations (Datta et al., 2006, Singh et al., 2016; Katt et al., 2018).  
a a 
b 
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1.6 Functions of TG2 
 
The enormous array of tissue transglutaminase functions in the cell are both enzymatic and 
non-enzymatic.  
1.6.1 Deamination function  
 
In deamination reactions catalysed by TG2, an amide functional group in the glutamyl side 
chain of a protein is replaced with water, and the result is glutamic acid (fig 1.6a). Introduction 
of such into proteins affects their activity, conformation and ability to interact with other 
proteins. Such reactions are encouraged by low pH, low substrates and TG2 concentrations. 
An example is in that of the wheat protein gliadin, where TG2 catalysed deamination reactions 
are linked to celiac disease (as reviewed by Nurminskaya and Belkin, 2012). 
1.6.2 Transamination function 
Another enzymatic function of TG2 is its transamination activity, which facilitates the addition 
of an amine group into an existing protein molecule. The amino nitrogen from the substrate 
for the reaction (donor) is transferred to a keto acid which serves as the receptor (Lorand and 
Graham, 2003). Such an addition results in one of two outcomes: a post-translational 
modification, which changes the unique characteristics of the protein, or the formation of an 
iso-peptide bond, which crosslinks two proteins. Such bonds are resistant to proteolytic 
chemical and physical forces. These bonds have been proposed to stabilise the extracellular 
matrix, thus averting the release of apoptotic cells’ content into the environment (Gundemir et 
al., 2012). 
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Figure 1.6: Transglutaminase catalysed reactions (a) deamidation and (b) transamidation 
 
1.6.3 Protein-Protein cross-linking/ GTPase / ATPase function  
Protein cross-linking is one of the various and most studied enzymatic reactions catalysed by 
this enzyme. TG2 crosslinks itself to other cellular proteins through its lysine residues and to 
substrates containing glutamyl, such as the gluten peptides and extracellular matrix proteins 
(fibrinogen and fibronectin). The simultaneous existence of both reactive lysine and glutamyl 
residues facilitates TG2 to create isopeptide crosslinks between molecules that can affect the 
interaction, conformation and stability of proteins; perhaps significantly these isopeptide bonds 
are usually very resilient to polymerisation (Nurminskaya and Belkin. 2012). TG2 is involved 
in GTP-binding and also functions as a G-protein receptor  (Nakaoka et al., 1994) and has 
identical α subunits with the GTP binding protein Ghα, and its GTPase, cross-linking activity 
is under the control of cofactors Ca2+ and GDP.  
1.6.4 Protein phosphorylation 
 
Protein phosphorylation is also a post-translational modification caused by the covalent 
attachment of a phosphoryl group to a protein side-chain(s), usually tyrosine, threonine or 
serine. Such modifications play an essential role in regulating protein-protein interactions and 
functions (Wang et al., 2012). TG2 has been observed to have intrinsic serine/threonine kinase 
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activity and involved in several phosphorylation reactions. Of potential importance to the 
control of apoptosis, TG2 phosphorylates p53 at serine residues 15, and 30, which are 
essential interaction sites with Mdm2.   p53 is a tumour suppressor protein which when 
activated by phosphorylation induces genes involved in DNA repair and cell cycle arrest, 
especially from the G2 and M phases. Activation of p53 involves destabilising the interaction 
between Mdm2 and p53, which results in cell cycle arrest and apoptosis (section 1.15.2). 
Thus, the TG2- induced phosphorylation decreases the capacity to interact with Mdm2 (Mishra 
and Murphy 2006).  
Histones are also known substrates for TG2 phosphorylation and cross-linking activity, and 
such modification alters chromatin structures, transcription, replication and gene expression 
(Sato et al.,2003). Histones H1, H2A, H2B, H3 and H4 phosphorylation has been shown to 
promote gene transcription (Dunn, 2003), and the phosphorylation of H1 mainly was 
associated with chromatin change in breast cancer cells (Mishra et al., 2006) and 
retinoblastoma proteins (pRb), a tumour suppressor protein (Mishra et al., 2007). 
1.7 Other functions of TG2 
Multiple physiological roles have been linked to TG2, as depicted in the ‘TG2 tree of life’ 
(figure1.7). Intracellularly, TG2 is thought to play opposing roles: a pro-apoptotic and an anti-
apoptotic part, depending on the cellular context and biological cues (Scondy and Fesus, 
2005). Extracellular TG2 is involved in cell adhesion (Gaudry et al., 1999; Gaudry et al., 
1999b), matrix assembly (Collighan and Griffin, 2009), wound healing (Telci 2006), receptor 
signalling and diverse other cellular activities.   
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Figure 1.7: Tissue transglutaminase 2 ‘tree of life.’ 
An illustration of the diverse functions of tissue transglutaminase 2, shown as a tree of life with different 
branches depicting the multifunctional nature of the protein. 
                                                                                                                                                         
1.8 Localisation and distribution of TG2  
TG2 is expressed abundantly in various organs such as the heart, liver, and intestine, as well 
as erythrocytes (Placentini and Fesus, 2002), where it is found in both intracellular and 
extracellular locations (Park et al., 2010). Intracellularly, TG2 is principally in the cytosol 
though it is also present in the nucleus, mitochondria and endoplasmic reticulum. 
Transamination activity is perceived to be latent in the cytosol due to the low calcium ion 
concentrations. However, it can be triggered by cellular stressors, which activate an influx of 
extracellular calcium or intracellular release from calcium stores and specific stimuli can cause 
the translocation of cytosolic TG2 into the nucleus. Approximately 5% of cellular TG2 is found 
in that compartment, where it functions as a G-protein or cross-links histones via its 
transamidation function (as reviewed by Onyekachi et al., 2015). 
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TG2 contained in the extracellular matrix (ECM) is shown to play an essential role in cell 
adhesion, migration, ECM organisation and turnover. TG2, therefore, contributes to routine 
wound healing, tissue regeneration, inflammation, and fibrosis. Due to its multifunctional, 
ubiquitous nature and interaction with different substrates, TG2 has been implicated in several 
pathological conditions, including multiple forms of human cancer (Zemskov et al., 2007). 
1.9 TG2 substrates  
 
As a ubiquitous protein, the array of TG2 substrates is enormous; this might account for its 
involvement in several cellular processes. TG2 substrates are distributed widely in the cytosol, 
nucleus, mitochondria and on the extracellular surface of the cell. Table 1.4 shows a list of 
TG2 substrates in the ECM with emphasis on substrates involved with signal transduction and 
cellular processes that can lead to cancer. A list of other substrates can be found in the 
appendix section. 
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Table 1.4: Some TG2 substrates in cells grouped by functions 
Substrate Involved in   
Nf-kβ 
PTEN 
AKT 
Histones 
p53 
Caspases 
Epidermal growth factor 
Latent TGF-beta binding protein-1 (LTBP-1) 
Cystatin 6 (M/E) 
Galectin 3 
Small GTPases 
Keratin, type II cytoskeletal 1 
Retinoblastoma 
Histones 
PKM2 
 
Cancer biology 
Osteonectin 
Osteopontin (extracellular matrix cell adhesion 
protein) 
Nidogen (entactin) 
Galectin 3 
Fibrinogen A alpha 
Fibronectin 
Collagen alpha 1(III) 
Cell adhesion molecule C-CAM 
SLC proteins 
Extracellular matrix-cell interaction and 
stabilization 
Loricrin 
Band 3 
Clathrin heavy chain 
Solute carrier proteins 
Focal adhesion kinase 
 
Membrane structure/function and membrane traffic 
Rho A 
Phospholipase A2 
Nucleotide(s) binding/hydrolysing 
Insulin-like growth factor-binding protein-3 
(IGFBP-3) 
Insulin-like growth factor-binding protein-1 
Integrins 
Fibronectin 
Osteoclasts 
Signal transduction 
Vimentin 
Tubulin 
Troponin T 
Microtubule-associated protein tau - Isoform Tau-F 
(Tau-4) 
 
 
Cytoskeleton regulation 
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1.10 TG2 isoforms 
 
Structurally, there are several isoforms of TG2, which are generated from alternative splicing 
of the mRNA transcript from the TG2 gene. Alternate splicing during gene expression offers 
the opportunity to make protein products with different functions from the parent gene and/or 
product.  The main alternatively, spliced forms of TG2 gene products include variants in the 
amino acid sequence of the C-terminal, resulting in the formation of a long variant (TG2-L) 
and a short variant (TG2-S). Other shorter variants have also been discovered (TG2-S2, TG2-
S3 and TG2-S4), which were produced by alternative polyadenylation, generating proteins with 
different C-termini; (Gentile et al.,1999; Phatek et al., 2013) the short variant (TG2-S) being 
highly expressed in Alzheimer’s disease brains, and it was proposed to be responsible for the 
noticeable increase in Ca2+-dependent TG2 crosslinking measured in AD brains (Citron et al. 
2001). 
Figure 1.8: shows the full-length protein with 687 amino acids and a molecular weight of 75 
kDa (Gentile et al., 1991); TG2-S which has a molecular weight of 52 kDa with 540 amino acid 
residues; and TG2-S2, which has a molecular weight of 38kDa with 349 amino acid residues 
respectively (Fraij and Gonzales 1996). These differentially spliced copies have a different 
function (Begg et al., 2006).  
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Figure 1.8: Schematic diagram of TG2 isoforms, (a) TG2-L (b) TG2-S (c) TG2S2. The numbers 
indicate the amino acids in each domain. 
 
Singh et al., (2010) demonstrated the effect of the different conformations of TG2 on the 
viability of cells and discovered that the disruption of the hydrogen bonds between the C-
terminal β barrel and the catalytic core maintains the protein in an ‘open state’ which causes 
cells to enter into apoptosis promoting cell death. In contrast, the ‘closed-form’ encouraged 
cell survival. TG2-S was seen to have a cytotoxic effect on NIH3T3 cells (Antonyak et al., 
2006; Hitomi et al., 2015) and on neuroblast cells; it was seen to have opposite effects to TG2-
L (Tee et al., 2010). 
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Figure 1.9: Schematic diagram of the conformational states of the full length and truncated 
TG2-S variants. The truncated variants supposedly are always in the ‘open state’.  
 
The expression of the shorter variant (TG2-S) is usually lower than the full-length variant (TG2-
L) as seen in healthy cells, but there is more variation in the expression of the isoforms in 
cancer cells. However, TG2-L contributes approximately 50-60 % of the total TG2 expression 
showing the variability of TG2 splicing among cell lines (Phatek et al., 2013). 
1.10.1 TG2-L and TG2-S in cell proliferation and cell death. 
 
The multiple biological functions of TG2 include the propagation of signals that encourage the 
survival of cells in some circumstances, and cell death in others. The possible association 
between TG2-facilitated cell malignancy and survival is relevant since increasing evidence 
has shown that inhibition of TG2 enhances apoptosis in cancer cells (Budillon et al., 2013). 
The expression of  TG2 variant forms is altered in several cancers (Phatek et al., 2013), which 
may suggest that the differential levels expressed may play a significant role in the cellular 
crosstalk involved in driving cells into apoptosis or survival. From previous findings, TG2-L 
expression in fibroblast, as well as in cancer cells, protects against apoptosis while the 
expression of TG2-S induced apoptosis. The pro-apoptotic action of TG2-S was not due to 
the GTP-binding activity because it exhibits a weak transamidation activity, owing to the 
truncated C-terminal, which removes the guanine binding site. The apoptotic ability of TG2-S 
was seen to be due to a rare capacity that the isoform has to displays a complex form of 
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abnormal aggregation, such abnormal oligomerisation has been seen as a mechanism for cell 
death induction. Hence, mutated, misfolded or posttranslational modified proteins that attain 
the capacity to oligomerise randomly can accumulate in cells, disrupting normal cellular 
processes and thus lead to cell death ( Antonyak et al., 2006). Based on the conformation 
shown in figure 1.9, TG2-S is always in the ‘open state’, emphasising the significance of the 
last 30 amino acids, including Arg 579 which plays a vital role in cell division (Frezza and 
Mauro, 2015) and whose absence may be responsible for TG2-S cytotoxic nature. 
Using fibroblast cells with a Myc-tagged form of TG2, Antonyak et al.,(2011), showed that 
TG2-L actively protected the cells from apoptosis due to serum starvation, by inducing 
increased levels of the mammalian target of rapamycin/viral accessory protein p13 
(mTor/P13complex 1, p70-S6-kinase pathway and proto-oncogene c-Src (c-SRC) binding 
which promotes cell survival. When cells were treated with inhibitors that block TG2 function 
and c-Src kinase activity, the mTor/P13complex 1, p70 S6-kinase pathway was interrupted, 
eliminating the TG2-mediated survival of cells. TG2-L was also observed to encourage the 
survival of malignant mesothelia in hypoxia (Zonca et al., 2017). 
1.11 The cell cycle  
 
Cell differentiation, division and cell death are major biological processes that control 
homeostasis in multicellular organisms; intricate pathways regulate genomic integrity, growth 
and survival of cells. In these pathways, DNA repair, programmed cell death and cell cycle 
checkpoints have critical roles, and interruption or poor regulation of cell death pathways may 
lead to abnormal cell growth (Wiman and Zhivotovsky, 2017).   
Malfunction of the cell cycle plays significant roles in the development of several disorders 
such as cardiovascular and neurodegenerative diseases, and cancer. Increased 
understanding of the mechanisms of these diseases has directed the development of new 
therapeutics for pathology linked with cell cycle irregularities (Wiman and Zhivotovsky, 2017).   
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Cyclins and cyclin-dependent kinases (CDKs) are specific proteins responsible for driving the 
cell forward in the cell cycle phases G1, S, G2, and M (Malumbres and Barbacid, 2009). A 
vital step in the cell cycle that is carefully regulated is the G1 to S transition because as soon 
as the cell enters the S phase, it is destined to go through the subsequent phases to give rise 
to daughter cells (Wiman and Zhivotovsky, 2017). CDK complexes can be inhibited by p21 
(cyclin-dependent kinase inhibitor 1), and p21 was demonstrated to be induced by miR-184 
which are short (18-25) nucleotides of non-coding RNA (Richardson et al., 2018). Inhibition of 
the CDK complexes will affect the progression of the cell cycle and cell division. 
Two hallmarks of cancer, as shown in figure 1.10, are the disregard for signals of programmed 
cell death and continuous proliferation (Hanahan and Weinberg, 2011). Abnormal growth at 
the molecular level is often due to the activation of oncogenes such as Ras and Myc and the 
disruption of the retinoblastoma protein (pRB) controlled regulation of G1 to S phase. pRB is 
a tumour suppressor protein whose role in the cell cycle is to prevent excessive replication 
and acts as the ‘brake’ in the cell. Indeed many tumours display a genetic change that alters 
the function of pRB. Recent progress in the knowledge of the cell cycle and cell death has 
shown that molecular targeting of key biomarkers may provide new targets for enhanced 
cancer treatment (Wiman and Zhivotovsky, 2017).   
pRB is a substrate for TG2 (Table 1.4), and it was observed that TG2 phosphorylates pRB at 
Ser780 which resulted in the destabilisation of the pRb·E2F1 complex, an essential requirement 
for the progression of the cell cycle (Lian et al., 2010). 
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Figure 1.10: The ten hallmarks of cancer  
The defence mechanisms exhibited by cancer cells which serve as a framework to understand 
tumour pathogenesis. 
 
1.12 Cancer and chemoresistance 
Chemoresistance is defined as the resistance of cells to the action of a specific therapeutic 
agent(s). (Stedman, 2005). Tumours can be innately resistant preceding chemotherapy or 
develop chemoresistance during the treatment process, to develop a phenotype that is cross-
resistant to a variety of related-chemotherapeutic agents (Gore et al., 2015). Chemoresistance 
is the primary cause of treatment failure and is more pronounced in advanced metastatic 
disease, in the majority of patients (Longley et al., 2006).  
In a similar way to how alterations in bacteria produce infections that are resistant to 
antibiotics, changes in cancer cells produce tumours that are resistant to treatments that were 
previously effective . Relapse in cancer patients is believed to be due to the growth of a small 
percentage of cells that escape death and mutate into these resistant forms (Forsythe,2010). 
Initially, the patient may show significant improvement until the new form of cancer 
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establishes. Such resistance to anti-cancer drugs is a primary problem encountered and a 
leading cause of treatment failure, in addition to other factors (fig 1.11), such as 
pharmacological and cellular factors (Gore et al., 2015). Despite targeted therapeutics and 
specific treatment approaches, it seems likely that resistance will continue to be a significant 
clinical problem (Gatti and Zunino, 2005) because cancer cells still develop resistance to novel 
chemotherapeutic drugs. 
1.13 Molecular mechanisms of chemoresistance  
 
The problem of chemoresistance is multidimensional, and several factors affect tumour drug 
sensitivity. However, evidence has emerged from research over recent decades that can 
partially explain the mechanisms of resistance (Longley et al.,2006). These processes include 
the reduction of active drug concentration at the target level, due to activation of transporter 
proteins, detoxification mechanisms within the cell, alterations affecting drug-target 
interactions and induction of factors that influence cellular responses that affecting tumour cell 
survival (Fig 1.11). 
A key drug-resistance mechanism in cancer cells is the ability to decrease drug concentration 
at the drug target. Two possible mechanisms capable of reducing drug concentration at the 
target site includes reduced drug uptake or enhanced drug efflux. Drug transporters aim to 
remove chemotherapeutic drugs from the cell, and this mechanism is a natural defence by 
which means the tumour cells can evade the action of the drug (Kachalaki et al., 2013). 
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Figure 1.11: Mechanisms of chemoresistance. (Adapted from Gatti and Zunino, 2005) 
An illustration of the resistance mechanisms by cells. (a) represents the drug transporters P-
glycoprotein 1 (P-gp), multidrug-resistant associated protein (MRP) and breast cancer resistance 
protein (BCRP). (b) the drug target site such as the DNA; (c) cellular response to the drug: cell cycle 
arrest, initiation of apoptosis or cell survival.  
 
1.13.1 Resistance mechanisms of cancer cells 
 
The strategies employed by cancer cells to evade the effect of anti-cancer drugs are described 
in this section.  
1.13.2 Drug transporters  
Most drugs are transported from the digestive tract into the portal blood vessel, but drug 
bioavailability at the site of action is dependent upon local cellular active transport processes 
(Zhou, 2010). Based on metabolic needs or the presence of toxic substances, membrane 
transporters relocate substances in and out of cells (Cucillo et al., 2016).  
(a) 
 
 
 
(b) 
 
 
(c) 
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Several cytotoxins found naturally and used in chemotherapy as drugs enter cells by passive 
diffusion, and these amphipathic drugs are hydrophobic enough to diffuse through a lipid 
bilayer but also hydrophilic enough to reach their target (Gatti and Zunino, 2005).  
A decrease in drug influx, as well as increase of efflux from the cells, may reduce the 
accumulation of drug inside the cell, as most chemotherapeutic drugs move into cells via 
passive diffusion through the plasma membrane. Thus, changes in the cell membrane structure 
associated with oncogenes will also affect drug influx (Bush and Li, 2002).  
The ATP-binding cassette (ABC) family of proteins is responsible for influencing the 
intracellular concentration of drugs and several compounds in cells and tissues (Gatti et al., 
2005). Approximately 49 ABC transporter genes have been discovered in the human genome, 
which are expressed naturally in a diversity of tissues remove xenobiotics from the body 
(Kachalaki et al., 2013). 
Drug transporters typically are composed of two transmembrane domains that recognise and 
translocate substances through the plasma membrane and two other nucleotide-binding 
domains, which help to generate the energy needed, by the hydrolysis of ATP (Kachalaki et 
al., 2013).  
1.13.3 Modifications of drug targets 
Any alteration or modification in the expression levels of the drug target during patient 
treatment can lead to resistance. An example of such change is with the antimetabolite drug 
5-Fluorouracil, which inside the cell is converted to the compound fluorodeoxyuridine 
monophosphate (FdUMP). FdUMP is a strong inhibitor of the enzyme thymidylate synthase 
(TS) which is needed for DNA synthesis (Longley et al., 2003). An increase in TS affects the 
quantity of 5FU required to inhibit all targets, and if insufficient, cancer cells will continue 
multiplying (Kachalaki et al., 2016). Research has shown that patients with elevated levels of 
TS were resistant to chemotherapy when compared with responsive patients (Leichman et al., 
1997). 
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Another example is that of decreased oestrogen receptor expression in oestrogen positive 
breast cancer cells which leads to the failure of tamoxifen, a major drug of choice for treatment 
to subdue cell growth (Miller, 2004; Campos 2004).  
1.13.4 Cellular response to chemotherapeutic agents 
There are several different cellular responses to chemotherapeutic agents, and the initiation 
of DNA repair processes is considered to be the first and most frequent response of cells to 
toxic damage. Cells have developed complex signalling pathways to stop cell cycle 
progression in the presence of DNA damage, thus facilitating DNA repair (Zhou et al., 2000; 
Friedberg, E. C. 2003). However, when the impact of cellular insult surpasses cellular ability 
to repair, cells enter into apoptosis (Cory and Adams, 2002). 
1.13.5 Alterations in DNA damage repair  
Cells can develop chemoresistance following recovery from DNA damage probably caused 
by oncosis.  The excision repair cross-complementing protein group 1 (ERCC1), which is a 
DNA-repair protein, has been shown to be prominent in platinum-based drug resistance and 
the overexpression of this protein correlates with platinum drug resistance in certain cancers, 
such as non-small cell lung cancers, ovarian and gastric cancers (Chang et al. 2005; Olaussen 
et al., 2006; Bouwman and Jonkers, 2012). 
1.13.6 Problems with cell cycle regulation 
The tumour suppressor protein (p53) is encoded in humans by the homologous gene TP53 
and functions as a tumour suppressor gene by regulating the cell cycle, DNA repairs and 
inducing apoptosis (Khoury and Bourdon, 2003).  p53 controls apoptosis and cell cycle arrest 
after DNA damage and prevents the production of new daughter cells with damaged DNA 
(Lowe et al., 2004; Kachalaki et al., 2016). p53 controls the G1 to S phase and also at the 
G2/M phases, and its activation promotes cell cycle arrest and encourages DNA repair or 
triggers apoptosis. Therefore, its inactivation has dire consequences in cells, leading to the 
emergence of several cancers (Kapil and Fok 2007).  
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Previous reports have revealed that in healthy growing cells, p53 translocates between the 
nucleus and cytoplasm, but when the cell is under stress such as in cases of hypoxia, UV 
irradiation or in the presence of chemotherapeutic drugs, p53 stabilises its location in the 
nucleus (Mesaeli and Philipson, 2003). In the nucleus, p53 binds to DNA stimulating the 
production of p21Cip1 (CDK-interacting protein 1) which interacts with cdk2, a cell division 
stimulating protein. The interaction between p21Cip1 and cdk2 prevents the cell from advancing 
to the next cell division stage with the resultant cell cycle arrest and apoptosis. So, a mutant 
p53 will be unable to bind to DNA effectively with the resultant consequence that p21Cip1 cannot 
act with cdk2 to stop the cell proliferation. Thus, cell division continues uncontrollably leading 
to the production of abnormal daughter cells resulting in tumours (NCBI 1998; Zukerman et 
al., 2009).  
Increased expression and/or mutation of the p53 gene has been linked with poor breast cancer 
prognosis, chemotherapy radiotherapy. Cancer is an example where the normal machinery of 
the cell cycle regulation is defective, with either decreased removal of abnormal cells and/or 
an overproliferation of cells (King and Cidlowski,1998) and, the tumour suppressor gene is a 
significant player (Pucci et al., 2000). 
Another essential regulator of cell cycle progression is the phosphatase and tensin homolog 
(PTEN) protein which is also involved in tumour suppression activities, such as inhibition of 
cell growth, migration, invasion and focal adhesion (Kapil and Fok 2007). It induces cell cycle 
arrest by upregulating p27KIP1 (a member of the universal cyclin-dependent kinase inhibitor 
(CDKI) family), a cell cycle inhibitor, and collaboration between p53and p27KIP1 appears critical 
in cancer development (Minami et al., 2016). 
1.13.7 Changes in B-cell lymphoma 2 (Bcl-2) regulation  
The Bcl-2 family of proteins regulates and activates caspases, which are the essential 
effectors of apoptosis. The Bcl-2 family contains both anti-apoptotic and pro-apoptotic 
proteins, and the pro-apoptotic members initiate the activities of the caspases leading to 
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apoptosis.  Previously, a study has shown an association between high expressions of Bcl-2 
in cancers with reduced response to anti-cancer agents (Kachalaki et al., 2016). 
1.14 Overcoming chemoresistance 
 
Resolving the problem of chemoresistance is essential in cancer treatment, and different 
approaches have been investigated to solve this problem. The suppression of genes involved 
in chemoresistance through the silencing of specific mRNA was found to be an effective 
method and is perhaps amongst the most advanced techniques currently used. Notably, the 
method was used to increase the sensitivity of human leukaemia cells (HL-60)  to Etoposide 
(a chemotherapy medication used for the treatments of leukaemia)  by using specific siRNA 
to suppress the multidrug resistance gene -1 (MDR-1 gene) (Kachalaki et al., 2015). 
TG2 has been linked with several pathological processes including cancer and 
chemoresistance, and the biological functions of TG2 are based on the capability to catalyse 
crosslinking reactions in the presence of Ca2+ ions (Mehta and Han, 2011). 
Under normal physiological conditions, due to the low Ca2+ and high GTP levels in cells, TG2 
acts as a scaffold protein involved in critical signalling pathways. Activation of these pathways 
(NF-kβ, AKT and focal adhesion kinase) results in the survival of cells (Lee et al.,2004; 
Chhabra et al.,2009; Kim et al.,2006; Mehta et al., 2010). 
Conversely, under trauma, stress or other extreme cellular conditions with a resultant loss of 
Ca2+ homeostasis, TG2 is activated, which results in its crosslinking of proteins and apoptosis 
of cells. Thus, TG2 functions in either cell survival or cell death and acts as a double-edged 
sword (Mehta and Han, 2011). Downregulation of proteins which promotes chemoresistance 
could revert resistance rendering tumours more sensitive to anti-cancer drugs.  
1.15 TG2, cancer and chemoresistance 
 
The wide range of TG2 biochemical activities accounts for its involvement with a variety of 
proteins and cellular processes (as reviewed by Nurminskaya and Belkin (2012). Most 
 36 
 
oncogene/tumour suppressor genes produce proteins that have a role(s) in the control of cell 
cycle progression. One such family of proteins are the integrins, a family of proteins which 
allow cells to be sensitive to signals in the environment from the ECM. These signals are vital 
for most cell types about proliferation, adhesion, survival, migration and differentiation. Indeed, 
integrin-arbitrated signals are essential at the checkpoint where cells advance from the G1 to 
the S phase (see cell cycle section 1.11) and send signals for growth (Moreno-Layseca et al., 
2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12: Some proteins modulated by TG2 whose alteration has a negative effect on 
proliferation   
 
Depending on the type of protein interacting with integrins, the signalling function and binding 
activity can be changed, which in turn can lead to a change(s) in the behaviour of the cell 
(Verma and Mehta, 2007). TG2 is such a modulating protein (fig 1.11), which forms complexes 
with a large percentage of integrins on cell surfaces and with other ECM proteins such as 
osteonectin, osteopontin, collagen, vitronectin and fibronectin, proteins which are also 
involved in apoptosis, signal transduction, invasion, metastasis and cell adhesion. These cell 
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cycle molecules either directly or indirectly are linked with the cell cycle and cell homeostasis, 
and any disturbance to the equilibrium gives rise to a dysfunctional system and pathogenesis 
(Mangala and Mehta, 2005). 
The interaction of TG2 with a significant number of ECM protein, fibronectin (figure 1.11), 
which are involved in cell survival signals has been shown to stimulate focal adhesion kinase 
leading to the activation of numerous signalling pathway that promotes the development of 
resistant phenotypes in breast cancer cells (Herman et al., 2006).  
1.15.1 TG2 and inflammation 
 
Inflammation which means ‘set on fire’ is a complicated biological response which is elicited 
by harmful stimuli. Inflammation involves a series of events such as cell proliferation, 
migration, neovascularisation, stabilisation of the ECM, and apoptosis which are all required 
for tissue repair and wound healing (Mehta and Han, 2011). 
Inflammation is a component of tumour progression, and indeed it is possible that many 
cancers stem from chronic irritation, infection and inflammation. The tumour microenvironment 
is composed mainly of inflammatory cells such as interleukins, tumour necrosis factor, 
interferon-gamma and the granulocyte-macrophage colony-stimulating factor which 
participates in the tumorigenic process encouraging survival, proliferation and migration. Also, 
tumours have adapted some signalling molecules such as chemokines and selectins from the 
innate immune system for migration, invasion, and metastasis (Coussens and Werb, 2012). 
For example, the body’s response to cancer has many similarities to inflammation pathology. 
Inflammatory cytokines and cells found at tumour sites are more inclined to aid proliferation 
and the progression of tumours than stimulating an anti-tumour response. Susceptibility and 
severity of cancer may be linked with changes of the inflammatory cytokine genes because 
inhibition or deletion of these genes inhibited the development of cancer (Ballenul and 
Mantovani, 2001). 
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Proinflammatory cytokines induce TG2, and interferon-ϒ (IFN-ϒ) and this synergism between 
IFN-ϒ and TG2 have been suggested to aggravate coeliac disease (Bayardo et al., 2012). 
1.15.2 TG2 and p53 
 
The translocation of p53 between the cytoplasm and nucleus is regulated by the murine double 
minute gene (Mdm2), and a defect in this interaction affects p53 function. Though it is a 
cytosolic protein, TG2, can translocate under certain situations to the nucleus and has been 
observed to phosphorylate p53 at Ser13 and Ser 20, reducing the ability of p53 to interact with 
Mdm2 (Mesaeli and Philipson,2003). Ser13 and Ser 20 residues are essential in the Mdm2-p53 
interaction (Mishra and Murphy. 2006). 
1.15.3 TG2, NF-κB and breast cancer 
 
The pleomorphic nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
protein family plays a vital role in inflammation and the immune system. Due to its essential 
role in controlling pro-inflammatory genes by protecting abnormal cells from apoptosis, it has 
been linked to cancer initiation and progression (Hoesel et al., 2013), and is involved in 
mammary tissue development. NF-κB plays a significant role in breast cancer, owing to its 
ability to activate the expression of multiple anti-apoptotic and angiogenic genes directly 
(Brown, 2012). Increased TG2 expression has been correlated with increased expression of 
proteins involved with aggressive breast cancer such as NF-κB, hypoxia-inducible factor and 
protein kinase B (Kumar and Mehta, 2012).  A relationship has also been observed between 
elevated TG2 levels and increased NF-κB levels and activity in pancreatic and breast cancer 
cells (Agnihotri et al., 2013). 
1.15.4 TG2 and metastasis  
 
Metastasis is a common reason for cancer-linked deaths, including breast cancer-related 
deaths (section 1.2). The stages leading to metastasis are intertwined, cells detach from 
original sites, invade blood vessels lumen and proliferate in other tissues different from the 
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original tumour site. The association of TG2-L with integrin and fibronectin promotes both 
adhesion and cell motility of cancerous cells, and the interaction promotes cell survival by 
rendering them resistant to apoptosis (Mangala and Mehta, 2005).  
In MDA-MB231, a metastatic breast cancer cell line, TG2 was demonstrated to interact with 
integrins B1, B4 and B5 and fibronectin (figure 1.12) which facilitate ECM adhesion. The 
increased expression of TG2 was also seen to increase the invasion of breast cancer cells 
attached to fibronectin-coated surfaces. The authors concluded that TG2 expression in breast 
cancer cells plays a vital role in the development of the metastatic phenotype (Mangala et al., 
2007). TG2 was then shown to induce EMT in different tumours, and the GTP binding activity 
was demonstrated to be responsible in ovarian cells (Shao et al., 2009; Cao et al., 2012) and 
mammary epithelial cells (Kumar et al., 2012).  
miRNA is involved in various cellular processes and has been linked with the progression of 
cancer. It has been demonstrated to have roles in the regulation of tumour cell survival and 
proliferation (Hu et al., 2016). Furthermore, Seo et al. (2019) demonstrated that TG2 induces 
EMT by inhibiting miRNA-205 (miR-205). 
1.15.5 TG2 in autophagy 
 
TG2 plays varying roles in activating the different forms of programmed cell death: necrosis, 
apoptosis and autophagy (figure 1.13). Autophagy is a mechanism of metabolic and 
chemotherapeutic stress tolerance, where cells devour fragments of themselves to persist in 
the face of starvation and stress (Kroemer et al., 2009). Its induction has both pro-apoptotic 
and pro-survival roles which contribute to the efficacy of chemotherapeutic agents as well as 
drug resistance. Overexpression of pro-apoptotic Bcl-2/Bcl-xL proteins. autophagy can be 
induced after ischemia, and anti-apoptotic Bcl-2 inhibits autophagy under nutritional stress 
(Degenhard et al., 2006).   
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 A study with MCF-7 cells revealed that epirubicin (EPI) a cancer medication, induced 
autophagy and the EPI-induced autophagy gave protection to the MCF-7 cells from EPI-
induced apoptosis (Sun et al., 2013). Defective autophagy may contribute to chemoresistance, 
and research has shown that inhibiting the expression of TG2 in pancreatic cancer cells by 
siRNA leads to the initiation of autophagy, and finally to cell death (Akar et al., 2002). 
Figure 1.13: Different types of programmed cell death with cellular response 
 
1.15.6 TG2 in apoptosis  
 
It has been proposed that the transamidating activity of TG2 is a vital controller between 
autophagy and apoptosis (figure 1.14). Cho et al., 2010, showed that the knockdown of 
endogenous TG2 caused a significant increase of caspase-3 activity and poly (ADP-ribose) 
polymerase (PARP) cleavage in mouse embryonic fibroblasts (MEF) cells exposed to 
apoptotic stimuli, and the same cells displayed the build-up of light chain (LC3)  following 
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autophagy induction. The authors suggested that the transamidating activity of TG2 confers a 
protective role in MEF cells response to death stimuli because inactive C277 mutant TG2 
suppressed caspase 3 and PARP but catalysed the final stages of autophagosome formation 
(Cho et al.,2010). Increased TG2 expression was also seen to inhibit apoptosis through 
suppression of the activity of caspase 3 and 9, which aids the release of cytochrome c into the 
cytosol and mitochondria membrane depolarisation (Rossin et al., 2011). 
 
 
 
 
 
 
 
Figure 1.14: Effect of TG2 transamidating activity on apoptosis and autophagy. 
An illustration showing the transamidating activity of TG2 is essential for the induction of apoptosis.  
 
  
1.15.7 TG2 and endocytosis 
 
Extracellular materials are taken into the cells by vesicles located on the plasma membrane 
through a process known as endocytosis. The uptake of fluids or macromolecules by vesicles 
into the cells is known as pinocytosis, while phagocytosis refers to the engulfment of larger 
particles. TG2 has been shown to interact with intracellular transport vesicles and is involved 
in endosomal trafficking, phagocytosis and pinocytosis (Kawabe et al., 2012). Also, drug 
delivery vectors play roles in the pharmacokinetics and toxicity challenges associated with 
non-viral intracellular delivery. Membrane trafficking is an important route for drug delivery into 
the cytosol, and such systems could be exploited for cytosolic drug delivery (Dyer et al., 2011). 
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A previous study with hepatocarcinoma cells (Meshram et al., 2017), provided evidence that 
elevated TG2 levels hindered the uptake of cisplatin into cells with a change in isoform ratios, 
which was associated with chemoresistance. The authors demonstrated that the isoform 
predominant in the cytosol was the long-form (TG2-L) while the membrane fraction of the cell 
is made up mainly of the short form (TG2-S). This confirms an earlier study by Milakovic et al., 
(2004) who showed that TG2 is predominant in the cytosol, present in the nucleus and 
associates with the plasma membrane. Thus the intracellular location of TG2 isoforms could 
have a bearing on its functions and cellular interactions with other proteins. 
1.16 TG2 compensation by other family members  
 
Though the functions of TG2 are diverse, no foetal abnormality was observed when TG2 was 
silenced in mice, which suggests that there may be a form of compensation by other members 
of the family. Also, there is no human disease traceable to the deficiency of TG2 though there 
are suggestions of possible compensation by other members of the transglutaminase family 
(Deasey et al., 2013).  
Characterisation of the compensation mechanism of catalytically active transglutaminase was 
analysed from seven different tissues/organs obtained from both wild type and TG2-
knockdown mice. The data obtained revealed tissue-specific compensation based mechanism 
for the loss of TG2. A transcriptional compensational mechanism was seen in the liver and 
heart, and a functional compensation was observed in the skeletal/cartilaginous tissues while 
there was no form of TG2 compensation in the skeletal muscle (Deasey et al., 2013). 
1.17 Phytochemicals, diet and cancer 
 
Phytochemicals are naturally-occurring plant-derived compounds that provide plants with 
colour and flavour, deter predators and offer protection. These compounds are known to 
provide health benefits to man owing to their anti-inflammatory, anti-oxidant and anti-
proliferating properties. Furthermore, epidemiological evidence suggests that a fruit-rich diet 
containing high levels of phytochemicals, may reduce cancer risk, and it was proposed that 
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purified phytochemicals may, therefore, have therapeutic properties  (Budisan et al., 2017). 
Sulforaphane (SFN), a natural compound obtained from cauliflower and broccoli, has been 
shown to have anti-cancer activities ( Zhang et al., 1992; Surh et al., 2003). SFN also protected 
against drug-induced hepatotoxicity induced by drugs such as cisplatin, microstatin, aflatoxin 
B1 and triptolide (Lu et al., 2014; Li et al., 2014; Gaona-Gaona et al., 2011). It has also been 
shown to protect human hepatocytes, and mice liver from cadmium selenium (CdSe) quantum 
dots (QDs) induced cytotoxicity used in disease diagnosis (Wang et al., 2015). 
Notable amongst such phytochemicals is vitamin A, a category of fat-soluble retinoid which 
includes retinal, retinyl esters and retinal. Vitamin A occurs in two forms: vitamin A and 
provitamin A carotenoids. Natural vitamin A is found in animal food sources such as fish, dairy 
and meat (highest in the liver) as retinoids, while in plants as carotenes (alpha-carotene, β-
carotenes and β-cryptoxanthin). Provitamins and the natural vitamin A precursors are 
converted by the body intracellularly into retinol and finally broken down to retinoic acid. 
Vitamin A can also be taken as a dietary supplement in the form of a multivitamin as retinyl 
palmitate or retinyl acetate, or preformed vitamin (Bruoso, 2019). 
Published reports exist on the relationship between diet and cancer, and these studies often 
focus on the likelihood of specific dietary components having a link with an increased or 
decreased cancer risk. Some of these studies have proven that certain compounds have pro- 
or anti-carcinogenic properties (NCI, 2015). A meta-analysis of dietary patterns and cancer 
risks suggests a potential role of diet in certain cancers, though the evidence was not 
conclusive (Guiseppe et al., 2015). Intake of dietary fat increased blood oestrogen levels, with 
the possibility of encouraging the development of breast cancer in women (Wu et al., 1999). 
Other studies suggested that retinoids could reduce cancer risk and the consumption of a diet 
rich in vitamin A, including β-carotene reduced risk in larynx, lung, bladder, mouth and cervical 
cancers. Conversely, other situations have linked retinoids to increased cancer risk under 
certain conditions (as reviewed by Graham, 1984). Retinoid could, therefore, be a two-edged 
sword reducing cancer risk in some cancers and increasing the risk in others.  
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From epidemiological studies, it was observed that there was a negative association between 
vitamin A rich food and the occurrence of several human cancers. However, high intake of 
dietary preformed Vitamin A was observed to result in teratogenicity in babies whose mothers 
consumed more than 10000 UI (3000 ug) of preformed of vitamin A daily (Rothman et al., 
1995). 
1.17.1 Retinoids and cancer 
 
RA activities in cells are coordinated by two families of nuclear receptors the retinoic acid 
receptors and the retinoid X receptors. These receptors function as ligands that bind to retinoic 
acid response elements on DNA and induces transcription factors that boost the transcription 
of specific genes (Zhu et al., 1997). 
Retinoids are generally used to treat dermatological and visual diseases though their role in 
cancer treatment and prevention has been investigated. Owing to their anti-proliferative, 
differentiation, anti-apoptotic and pro-apoptotic properties, they have been used as possible 
chemopreventive or chemotherapeutic agents (as reviewed by Bushue and Wan, 2010). Low 
vitamin A intake was seen to result in a much higher risk of developing cancer while altered 
retinoic acid receptor was associated with malignant transformation of cultured cells or animal 
tissues (Sun et al., 2002). Also, retinoids have been shown to suppress carcinogenesis in 
tumorigenic animal models of lung, skin, breast, ovarian and prostate diseases. Conversely, 
retinoids reversed premalignant human epithelial cells lesions and induced myeloid cells 
differentiation ( as reviewed by Bushue and Wan, 2010). 
1.17.2 Retinoids and breast cancer  
 
There have been several clinical trials with retinoids either by themselves or in combination 
with oestrogen inhibitors and interferons to prevent or treat breast cancer progression 
(Recchia et al., 2009; Veronesi et al.,2006; Zanardi et al.,2006). Retinoids inhibited mammary 
gland cancer in both animal models and human trials and were seen to be useful, especially 
at the early stages of the tumour progression, but with more aggressive tumours, the 
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effectiveness was reduced (Bushue and Wan, 2010). Expression of retinoic acid receptors 
(RARs) varies in lactating and post-lactating glands, likewise in healthy and malignant 
epithelial cells. RARs have also been linked to carcinogenesis (Zanardi et al.,2006). 
The expression of retinoic acid receptors (RARα, RARγ, RXRα, and RXRβ ) are the same 
amongst hormone-dependent breast cancer and hormone-independent breast cancer cells 
(Zujewski et al.,1999). The expression of RARβ gene is upregulated in healthy mammary cells 
upon retinoic acid treatment, and deficiency of its expression decreased treatment efficiency 
in aggressive breast cancers.  From the reports available, RA inhibition of breast cancer is 
linked with the expression of RARβ. Equally, In animal cell models, retinoids in combination 
with anti-oestrogens inhibit proliferation of cells in oestrogen receptor-positive metastatic 
breast cancer but are not effective in oestrogen receptor-negative metastatic cancers (as 
reviewed by Bushue and Wan, 2010). 
1.17.3 The argument for and against vitamin A in cancer progression  
 
Vitamin A is an essential requirement, as deficiency results in night blindness, and increased 
maternal mortality in pregnant women (Sommer, 2001). The required dietary allowance varies 
amongst children, men and women (see Table 1.5) and hypervitaminosis A has been linked 
with bone disorders, and alteration to the metabolism of some fat-soluble vitamins (Olson et 
al., 1987; Trumbo et al., 2001).  
There was an ongoing argument in the 1990s regarding the role played by vitamin A in cancer 
treatment and progression. Vitamin A was seen to amplify gene expression in breast cancer 
cells, encouraging stem cells surrounded by a tumour to transform into endothelial cells. These 
transformed cells were reported to generate blood vessels which link up to the main blood 
supply, encouraging further tumour growth (GUMC, 2008).  
Beta-carotene and vitamin A was seen to accelerate the progression of lung cancer during a 
clinical trial (Omenn et al., 1996), while a retinoid analogue fenretinide, was seen to prevent 
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breast cancer reoccurrence in pre-menopausal women, but elevated the risk in their 
postmenopausal counterparts (Veronica et al., 1999).  
Divergent views on studies with human prostate cancer revealed that inhibiting the breakdown 
of retinol to retinoic acid with VN/14-1 (retinoic acid metabolism blocking agent), decreased 
the tumour volume. The authors suggested that vitamin A precursors are essential for anti-
cancer activities in cells or retinoic acid is pro-oncogenic (Khandelwal et al., 2007). Another 
study revealed that the combination of vitamin A and vitamin C on cultured breast cancer cells 
inhibited growth by 75.5% when compared to the untreated control. The authors also proposed 
that vitamin C aids vitamin A inhibitory effect on the cells (Kim et al., 2006; Andrew,2008).  
Andrew W. Saul of the Orthomolecular Medicine News Service on August 20, 2008, had this 
to say:“ Vitamin A is very far from being a cancer "promoter." Rather, it is very near to the 
cancer solution.” The results generated from this present study, however, does not conform 
with this statement because RA was seen to be a cancer promoter than a solution (fig 5.7, fig 
5.8 and fig 5.9) 
The recommended dietary intake of vitamin A  is shown in Table 1.6. 
Table 1.5: Recommended vitamin A daily allowance (Trumbo et al., 2001). 
 
 
 
 
 
  
Age (years)/Gender  Required dietary allowance (µg) 
Male /9-13 600 
Female/9-13 600 
Male /19-50 900 
Female/19-50 700 
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1.18 Chemotherapeutic drugs 
There are different classes of chemotherapeutic drugs, based on their mechanism of action. 
These include the antimetabolites, DNA-interactive agents, hormonal therapies, monoclonal 
antibodies and molecular targeting agents (MacDonald, 2012). 
The mechanism of action of chemotherapeutic drugs belonging to the antimetabolites group 
operates through interruption of critical biosynthetic pathways. Structural equivalents of 
purines or pyrimidines may be incorporated into the cell which interrupts nucleic acid 
synthesis. An example in this class is 5-Fluorouracil (Nussbaumer et al., 2011).  
DNA-interactive agents constitute one of the largest and key anti-cancer drug families. They 
damage the DNA of cancer cells by the attachment of alkyl groups to the DNA bases. Another 
means by which they carry out their action on cells is by forming cross-links between the DNA 
strands, thus preventing replication (Nussbaumer et al., 2011) and platinum complexes such 
as cisplatin and oxaliplatin belong to this category. Some chemotherapeutic drugs also act as 
intercalating agents where they insert and bind to the bases of the DNA of the cancer cell. 
This union causes damage to DNA and interrupts replication. Examples in this group are the 
anthracyclines, which include doxorubicin and epirubicin (Thurston, 2006). 
Other classes of anticancer drugs include topoisomerase inhibitors, which inhibit the function 
of topoisomerases upsetting the geometry and function of DNA (Maulik et al., 2014). DNA-
cleaving agents cause strand cleavage at binding sites, and anti-tubulin agents, which inhibit 
microtubule dynamics throughout the cytoplasm and disrupt critical cellular functions 
(Thurston, 2006). 
1.18.1 The drug cisplatin 
 
In 1965, Barnett Rosenberg discovered cisplatin, described as the ‘penicillin of cancer’,  
because it was the first platinum-based chemotherapy drug to be developed, and still one of 
the most effective chemotherapy drugs widely used for cancer treatment. Discovering cisplatin 
([PtCl2(NH3)2] or CDDP]), cis-[Pt (II)(NH(3))(2)Cl(2])  (figure 1.15)  was a milestone in cancer 
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chemotherapy, which generated interest in the use of platinum(II) and other metal-containing 
compounds as potential anticancer drugs. Since the introduction of cisplatin into clinical trials, 
there has been a tremendous impact in cancer chemotherapy, which has altered the course 
of therapeutic management of various cancers, including those of the ovaries, bladder, testes, 
oesophagal, breast, cervical, stomach, prostate cancers, head and neck. Also, cisplatin is 
used in the treatment of metastatic ovarian cancer, metastatic testicular cancer and advanced 
bladder cancer. It is used in different aspects of chemotherapy, such as an antineoplastic 
chemotherapeutic drug, in adjuvant therapy and used in combination with radiation therapy 
(Florea and Besselberg, 2011). 
  
Figure 1.15: Cisplatin (Gómez-Ruiz et al., 2012)   
Chemical structure of cisplatin showing platinum flanked by two molecules of chlorine on the right and 
by ammonia on the left.    
                                                                    
Shapewise, cisplatin is flat and square, and its covalent bonds enable it to readily exchange 
molecules with other ligands in the body including water. Understanding the mode(s) of action 
of cisplatin has assisted in developing refined therapeutic methods that have improved the 
antitumor effect of the drug. However, the knowledge is far from complete, as the mechanisms 
underlying cells developing resistance, which significantly restricts the use of this class of 
drugs clinically, still represents a significant gap in our knowledge (Siddik, 2003). 
1.18.2 Mode of action 
 
The mechanism of action of cisplatin was the principal reason for its extensive use in cancer 
chemotherapy. CDDP is considered chiefly as a DNA-destructive chemotherapeutic drug, 
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where it forms platinum complexes inside the cell. Research shows that cisplatin loses its two 
chloride ions, and replaced by a hydroxy group making it a reactive species that readily binds 
to DNA bases at sites where guanine and adenine sit close to each other on the same strand 
(figure 1.16). It also forms cross-links between DNA strands and these changes on the strands 
interfere with cell function, especially with DNA replication and repair mechanism, which 
results in an arrest of the cell cycle followed by induction of apoptosis (Florea et al., 2011). 
 
 
Figure 1.16: Cisplatin´s mechanism of action, forming crosslinks with DNA (Gómez-Ruiz et al., 
2012). 
 
Cisplatin showed significant single-agent activity as front-line therapy in metastatic breast 
cancer (MBC) in a trial where twenty consecutive patients were treated with cisplatin 30 
mg/m2/d for four days every three weeks (Sledge et al., 1988). Also, preclinical data support 
the notion that BRCA1 associated breast cancers may be sensitive to anti-cancer agents that 
cause DNA damage such as cisplatin (Gronwald et al.,2012). 
1.18.3 Cellular uptake of cisplatin 
 
Cisplatin is administered as 75mg/m2 intravenously every three weeks for 30-120 minutes in 
a sterile intravenous solution of sodium chloride, and it enters the bloodstream still intact 
because of the high concentration of chloride ions (approximately 100 mM) (Silver et al., 
2010). Cisplatin enters into cells through active uptake though some cisplatin molecules are 
 50 
 
trafficked by passive diffusion owing to the low concentration of chlorine in the cell 
(approximately 3-20 mM). Figure 1.17 shows some of cisplatin cellular targets in the cell: RNA; 
DNA; methionine; mitochondria, sulphur-containing enzymes such as glutathione; 
metallothionein and some endogenous proteins. (Siddik et al., 2003). 
 
 
 
 
 
Figure 1.17: Figure 8 Cellular uptake of cisplatin indicating targets (red arrow) mitochondria; 
RNA; DNA, and metallothionein inside the Golgi apparatus.  
 
1.18.4 Cisplatin resistance in breast cancer 
 
When accompanied by surgery, adjuvant and neoadjuvant chemotherapies in breast cancer 
are an effective treatment. Amongst them, cisplatin is used widely as a cell cycle phase 
nonspecific agent in advanced breast cancer treatment, because of its known cytotoxic mode 
of action. Though cisplatin has been established to be an active anti-cancer agent for treating 
several types of cancers and an effective inducer of apoptosis, (Ormerod et al., 1996; Henkels 
and Turchi, 1997), the efficiency has not been seen in breast cancer often because of issues 
relating to the rapid development of chemoresistance (Siddik, 2003). 
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Resistance to cisplatin has been seen to develop when the tumour cells do not experience 
apoptosis at relevant clinical drug concentrations. Thus, the treatment of these tumours often 
requires drug concentrations that are cytotoxic to healthy cells. Resistant cells may be 
inhibited by cisplatin at levels as high as 50–100-fold more than the required concentration 
needed to inhibit sensitive tumour cells (Hills et al., 1989; Kelland et al.,1995; Hagopian et 
al.,1999). High doses can lead to severe toxicities in different organs, particularly the kidneys, 
bone marrow, and irritation to the digestive tract (Brabec et al., 2005). 
Cisplatin chemoresistance can be attained through prolonged exposure to the drug, or as a 
result of an intrinsic phenomenon (Saddik, 2003). From clinical studies, a two-fold increase in 
resistance was observed after the standard clinical dose was doubled (Perez, 1998). This 
effect is thought to arise due to intracellular variations that inhibit DNA damage signals from 
activating apoptosis and hindering cisplatin from forming interactions with DNA (Saddik, 
2003). Acquired cisplatin resistance, therefore, appears to be a multifaceted phenomenon that 
proves a considerable obstacle in the design of effective patient therapy (Xiu Chen et al., 
2016).   
The development of resistance and ways to overcome resistance has been the object of much 
ongoing research. Indeed, there could still be other mechanisms of cisplatin resistance not 
established, and this study aims to add to the growing wealth of knowledge by studying the 
roles TG2 isoforms play in the development of resistance to cisplatin.  
1.19 Studying chemoresistance 
 
One approach to studying chemotherapeutic drug resistance is the development of an 
experimental drug-resistant model, using the method of stepwise increases in drug 
concentration (Mc Dermont, 2014), a low-dose intermittent increase stimulus (Godwin et al., 
1992) or the pulsed treatment method,  where cells can recover in a drug-free medium, thus 
imitating the clinical pattern of chemotherapy (Stordal and Davey, 2009). As chemoresistance 
develops during drug administration, the exposure of cell lines to chemotherapeutic drugs can 
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serve as a beneficial tool for studying the dynamics fundamental to drug resistance (Yan et 
al., 2007). 
1.20 Research question of this project   
Previous research has suggested that maybe TG2 mechanism is involved in 
chemoresistance, but knowledge is scanty about relative expression and levels of the TG2 
isoforms in these processes. This research seeks to understand the relationship between TG2 
isoforms and chemoresistance, and could lay the foundation for novel anti-cancer treatments 
using TG2 short and long forms as specified targets.  
1.21 Research objectives  
1. To generate cisplatin-resistant cells from the MCF-7 breast cancer cell line. Immobilised 
analysis of chemoresistant cell lines will help to establish the relationship between the relative 
levels of expression of the isoforms and development of chemoresistance. 
2. To induce the overexpression of TG2 with retinoic acid, and to determine which isoform is 
induced, and determine the effect on the sensitivity of cells to cisplatin in both wild-type and 
resistant cells. 
3. To inhibit TG2 enzyme activity with cystamine in both sensitive and resistant cells, and 
determine the effect of inhibition on resistance. 
4. To use siRNA techniques to silence the TG2 gene in both wild-type and resistant cells with 
TG2-specific siRNA and determine the isoform(s) silenced and the effect of silencing on 
resistance. 
5. To compare the levels and ratio of TG2 isoforms in oestrogen receptor-positive (ER +ve) 
cells and the triple-negative breast cancer cell line, (HCC 1806) cells. 
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Chapter 2: Materials and Methods 
 
 
2.0 Pharmacologic agents 
 
All reagents were obtained from Sigma Aldrich unless otherwise stated.  
Cisplatin was dissolved in double-distilled water to prepare a  2 mM working stock solution. A 
fresh cisplatin solution was prepared in the dark and sterilised by passing through sterile filters 
for each experiment because the solution is unstable (Siddik et al., 2003). 
Cystamine dihydrochloride was dissolved in double-distilled water to make a 2 mM working 
solution. The solution was sterilised with sterile filters and stored at -200 C in aliquots.  
 A 10 mM retinoic acid stock solution was prepared by dissolving 3 mg/ml in absolute ethanol 
RA is UV, air and oxidising agents sensitive, the stock solution was prepared under subdued 
lighting in a glove bag under Aliquots were then stored at -200C.  
A 2mM stock solution of monodansylcardavarine was prepared by dissolving in 100µl 
methanol and made up with culture media, protected from light and stored in aliquots of 1ml 
in tubes at -200C. 
2.1 Cell lines and culture media 
All media used for this study was obtained from ThermoFisher Scientific and supplemented 
with 10% (50mls) of fetal bovine serum (FBS) and 1% penicillin-streptomycin (Invitrogen, UK) 
unless stated otherwise. 
The human MCF-7 breast cancer cell line (oestrogen positive) used for this study was obtained 
from the American Type Culture Collection (ATCC) and grown in DMEM medium., UK).  
The HCC1806 breast cancer cell line was obtained from the ATCC, grown in RPMI 1640 
medium. 
The human hepatocellular carcinoma (HEPG2) cell line, which expresses high levels of tissue 
transglutaminase 2, was also included to serve as a positive control. This cell line was 
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obtained from the European Collection of Animal Cell Cultures (ECACC) and grown in RPMI 
1640 medium. 
The cell cultures were maintained in an incubator at 370 C and 5% CO2  and regularly observed, 
changing the media every 2 days. Once cells were between 70-80% confluent, cell cultures 
were transferred to a new culture flask by dissociating cells from the flask with trypsin-EDTA 
(trypsinisation), centrifuged and transferred into a new flask labelled with the name of cells, 
passage number and date.  
2.2 Cell viability assay/ IC50 toxicity assay 
The viability of cells was determined using sensitive colourimetric assays for the determination 
of cell viability and cell proliferation. Cells were seeded in triplicate in 96-well plates at a 
concentration of 105 per well and allowed to adhere by incubating overnight in a humidified 
atmosphere at 370C and 5% CO2. The response of cells to chemotherapeutic agents was 
found by determining the minimum inhibitory concentration (IC50), which is the concentration 
of the drug required to inhibit 50% of the cells from growth (Benoit et al., 2012). The IC50 is 
measured using a dose-response curve. 
2.2.1 CCK-8 assay  
 
The Cell Counting Kit-8 (CCK-8) is made up of Dojindo’s highly water-soluble tetrazolium salt-
8 (WST-8). The soluble tetrazolium salt is reduced by dehydrogenase activities in viable cells 
to give a yellow-coloured formazan dye, which is soluble in the tissue culture media. The 
amount of formazan dye is proportional to the number of living cells in the assay (Dojindo, 
2012). Using the cell counting kit CCK-8, (Sigma Aldrich) and following the manufacturer’s 
protocols, 10 µl of CCK-8 was added to the wells containing the cells and chemotherapeutic 
agent(s) and incubated for  4 hours under constant culture conditions. Absorbance was read 
at 450 nm with an automated microplate reader ELx 800 (BioTek UK). The mean of the 
triplicates was calculated from three independent experiments and expressed as a percentage 
of the absorbance of the control cells, which had no drug treatments. 
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2.2.2 MTT assay  
Another type of cell viability assay uses the yellow 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay. NAD(P)H-dependent oxidoreductase enzymes in viable 
cells reduce the soluble yellow tetrazolium salts to an insoluble purple formazan and, the 
insoluble formazan compound is dissolved with a solubiliser SDS (sodium dodecyl sulfate). 
Cells were treated with increasing cisplatin concentration(s) for 24 hours before 25 µl of Cell 
Proliferation Kit I (MTT) was added to the wells. After 2 hours incubation, 100 µl of 10% SDS 
was also added to the wells and samples were incubated overnight. The absorbance was 
subsequently measured and read at 620 nm with the automated microplate reader ELx 800 
(BioTek UK). The mean of the triplicates was calculated from three independent absorbance 
readings and expressed as a percentage of the absorbance of the control cells, which had no 
drug treatment.   
   % of viable cells = Absorbance (sample) – Absorbance (blank)   x 100 
                                 Absorbance (control) – Absorbance (blank)    
 
 
2.3 Development of cisplatin-resistant cell lines.  
Drug-resistant cell lines were developed using a single dose exposure method (McDermott et 
al., 2014), modified by Meshram et al., (2017), with further modifications. Wild type cells were 
exposed to cisplatin for 24 hours at the IC50, and the growth medium was replaced with the 
drug-free medium until the cells were able to attain 80% confluence.  This process was 
repeated twice, and surviving resistant cells were subsequently maintained in drug-free media 
with appropriate supplements until they attained confluence.  
2.3.1 Test for resistance  
The IC50 of the wild type cells was compared with the resistant clones by the method described 
in section 2. 2. The disparity between the IC50’s of the resistant lines and those of the wild type 
cell lines indicates the level of resistance. The increase in resistance known as fold resistance 
was determined by the following equation: Fold resistance = IC50 of resistant cell line/IC50 
of the wild-type cell line (McDermott et al., 2014). 
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2.4 Preservation of cells  
A freezing medium made up of 90% growth medium, and 10% dimethylsulphoxide was 
prepared for cryopreservation of the cells. At 70% confluency, cells were harvested with 
trypsin, centrifuged for 5 minutes at 1500, rpm and pellets were loosened with the freezing 
medium. Approximately 1 x 106 cells were transferred into sterile freezing vials, placed in ‘Mr 
frosty’ (isopropanol solution), incubated in -800C overnight, and finally stored in liquid nitrogen.  
2.5 Flow cytometric analysis of apoptosis with propidium iodide and Annexin V 
 Flow cytometric analysis was carried out using Annexin V-FITC assay (BD Biosciences, San 
Diego) using a BD Accuri C6 flow cytometer (BD Biosciences, Europe). The Annexin V-FITC 
assay determines the level of phosphatidylserine (PS) on cell surfaces, and PI determines 
DNA levels. During apoptosis, PS translocates to the outer membrane, and fluorescently-
labelled Annexin V-FITC binds to it and is detected at an excitation of 488 nm and a 
wavelength of 525 nm using the flow cytometer.  The percentage of cells at different phases 
is measured when PI is plotted against Annexin V fluorescence. The cell populations are 
grouped into healthy, early apoptotic, late apoptotic and necrotic categories. Cells were grown 
to about 70% confluence, trypsinised, seeded at 1 × 105 cells in a 6-well plate, and allowed to 
adhere to the plates for 24 hours. Cells were then treated with either cisplatin, cystamine or 
retinoic acid, and incubated for the specified hours under physiological conditions of 5% CO2, 
37°C. After 24 hours, cells were trypsinised, washed and prepared for analysis. The cells were 
then analysed for apoptosis following the manufacturer´s directives (Annexin V-FITC assay) 
by adding 5 µl of Annexin V- FITC and 5 μl propidium iodide (PI) to the cells in the binding 
buffer before being incubated in the dark for 15 minutes. After the incubation period, 300 μl of 
binding buffer was added and the samples were analysed. Gating (selection of an area on the 
scatter plot with a specific population of cells) was used to locate viable single-cell events 
using the forward scatter (FSC), and side scatter (SSC) on the scatter plot. The gate was 
drawn to exclude events with low FSC, which represent cellular debris, and high SSC, which 
represents doublets from the analysis (see figure 2.1). 
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Figure 2.1: Gating limits for apoptosis by cytometry 
Illustration of the gating strategy, figure (a) shows how cell debris was excluded by comparing side 
scatter area (SSC-A) against forward scatter height (FSC-A). Figure (b) demonstrates the identification 
of single cells by comparing forward scatter height (FSC-H) against forward scatter area (FSC-A) which 
gates out cell doublets. Figure (c)  displays propidium iodide against Annexin V with cell population 
classified by colours, blue (healthy/ live cells); green (early apoptotic); red (late apoptotic) and black 
(necrotic).  
 
 
2.6 Protein extraction  
1 x 106 cells from both resistant and sensitive MCF-7 cells were lysed in the culture flasks with 
ice-cold radioimmunoprecipitation assay buffer (RIPA buffer) and protease inhibitor (Sigma 
Aldrich UK). The cell lysates were centrifuged at 4°C for 15 minutes (13,000 rpm), and the 
supernatant(s) containing the total protein lysate(s) were transferred to sterile Eppendorf tubes 
and stored at -80oC. Determination of protein concentrations was by the Bradford protein 
estimation method described by Lin et al., (2011). 
2.6.1 Bradford assay for protein quantification 
 
Protein concentration was determined using the Bradford assay kit (Abcam, ab102535), which 
is a fast and straightforward procedure to determine protein concentration in a sample. This 
method uses an enhanced Coomassie blue reagent, which interacts with the protein in the 
sample to produce a blue colour that is measured spectrophotometrically at 620 nm. A 
calibration curve is generated from a protein standard (BSA 1 mg/ml), and the concentration 
of the unknown sample extrapolated from the curve. According to the manufacturer's protocol, 
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5 µl of both Bradford reagent and sample were pipetted in duplicates into a 96-well plate and 
allowed to stand for 10 minutes at room temperature. After incubation, the absorbance of the 
samples was read with the automated microplate reader ELx 800 (BioTek UK), the intensity 
of the blue colour being proportional to the concentration of protein.  
2.7 Western blot analysis to determine TG2 protein expression  
 
Western blot analysis was performed following the protocol described by Kumar et al., (2011). 
Briefly, 50 µg of total protein from each sample were mixed with SDS sample buffer in 
Eppendorf tubes and placed on a heating block for 10 minutes at 80°C. Protein electrophoresis 
was performed using 10-12% NuPAGE Bis-Tris mini gels with MES Running Buffer 
(Invitrogen) at 150 V and 100 mA. After separation, gels containing the proteins were 
transferred onto nitrocellulose membranes at a voltage of 15 V and 60 mA for 1 hour and then 
blocked with 2% w/v bovine serum albumin solution for an hour. The membranes were washed 
thrice with TBS-Tween 20 (TBST) before probing with TG2 primary antibody (anti-TGM2 
mouse) at a dilution of 1:4000 at 4°C overnight (Table 2.1). Membranes were then washed 
thrice with TBST before further incubation with secondary antibodies (goat anti-mouse) at a 
dilution of 1: 4000 for 1 hour at room temperature. Membranes were subsequently washed 
with TBST before development with horseradish peroxidase (HRP) to show the different 
protein bands. Anti-beta actin antibody was used as a loading control at a 1:5000 dilution. 
Table 2.1: TG2 antibodies  
TG2 antibody Dilution 
Anti-Transglutaminase 2 antibody (CUB 7402). Primary monoclonal 
antibody. 
Goat Anti-Mouse IgG H&L (HRP) (ab07023). Secondary antibody 
Anti-beta actin antibody (AC-15) (ab6276) 
1:3000 
1:4000 
1:3000 
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2.7.1 Chemiluminescent blot detection 
Membranes were developed with the Clarity Western ECL Substrate (Biorad), which is 
compatible with HRP-conjugated antibodies ideal for film-based or digital imaging. The 
membrane was covered with equal volumes of both Clarity Western peroxide reagent and 
clarity Western luminol/Enhancer reagent and left at room temperature for 3 minutes. Excess 
fluid was drained off, and the membrane air-dried for digital imaging with the syngene GBOX 
CHEMI XRQ. 
2.7.2 Quantification of bands  
Bands from Western Blotting were quantified using the syngene GBOX CHEMI XRQ 
GeneTools analysis software to analyse and compute the intensity/density. Band density was 
subsequently represented as bar graphs. 
2.8 RNA extraction and reverse transcription PCR (RT-PCR) analysis 
 
The RT-PCR analysis detect the RNA expression of the TG2 isoforms. Total RNA was 
extracted from a million cells from both sensitive and resistant cell lines respectively using the 
Qiagen Rneasy Mini kit following the manufacturer’s protocol. Residual genomic DNA  
removed by the DNA elimination step in the protocol. The quantity and quality of RNA were 
determined spectrophotometrically with the NanoDrop 2000, and 3 µl of RNA was used in the 
reverse transcription PCR with TG2 primers from Eurofins Genomics (Table 2.2) and the iTaq 
universal SYBR® green one-step kit. Reverse transcription and PCR reaction were performed 
in one reaction in a LightCycler (LCS4 4.1.1.21). The PCR reactions were as follows: reverse 
transcription was for 10 mins at 50° C; denaturation 95°C for 5 min; amplification (40 cycles) 
at 95°C for 30 s; 60°C for 30 s and 72°C for 30 s. A melting curve, which checks the 
homogeneity of the amplified transcripts, was run between 72 and 95°C.  The analysis was 
performed in triplicate(s) with a negative control (sample without reverse transcriptase 
enzyme) to rule out possible contamination, and normalisation was done with the 
housekeeping gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase).        
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Table 2.2: Oligonucleotide sequence for TG2 isoforms and the housekeeping gene GAPDH. 
TG2 isoform name Primer sequence (5′ → 3′) Reference  
TGM2_v1 (TG2-L) F CCTTACGGAGTCCAACCTCA 
R CCGTCTTCTGCTCCTCAGTC 
Phatek et al., 2011 
TGM2_v2 (TG2-S) F ACCGCTGAGGAGTACGTCTG 
R TCAACAAATGCTCCAGGAA 
Phatek et al., 2011 
TG2 F TAAGAGATGCTGTGGAGGAG 
R CGAGCCCTGGTAGATAAA 
 Lingbao et al., 
2008. 
GAPDH F ACCACAGTCCATGCCATCAC 
R TCCACCACCCTGTTGCTGA 
Lingbao et al., 
2008 
 
Absolute quantifications was performed using the 2−ΔΔCt quantification method (Livak and 
Schmittgen 2001), and Table 2.3 shows how the values were computed. The average Ct 
values for the housekeeping gene, test gene (TG2 short and long forms) in both experimental 
and control conditions were computed as Gene being Tested Experimental (TE), Gene being 
Tested Control (TC), Housekeeping Gene Experimental (HE), and Housekeeping Gene 
Control (HC) (Phatek et al.,2013). 
Table 2.3: 2−ΔΔCt quantification method 
 
 
The ΔCt value was computed from the difference between TE and HE, TC and HC. 
                             ΔCt   = TECt value of TG2 isoform- HE Ct value of housekeeping gene                    
The ΔCt values calculated were for the experimental (ΔCTE) and control (ΔCTC) conditions, 
independently.  
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The difference between the experimental ΔCTE and control ΔCTC was computed to obtain 
the double delta Ct value (ΔΔCt): 
                              ΔΔCt = ΔCTE – ΔCTC. 
Finally, the expression fold change was calculated by 2^-ΔΔCt, as all calculations are in 
logarithm base 2 (Livak and Schmittgen, 2001), and presented as bar graphs (fig 4.9). 
2.9 Tissue transglutaminase enzyme activity assay 
 
2.9.1 Specific tissue transglutaminase colorimetric microassay (NBP1-37008) 
The Cov test uses biotinylated TG2 substrate-peptide (Biotin-pepT26) as the first substrate 
(amino acceptor acyl donor) and an amine donor acyl-acceptor as a second substrate. In the 
presence of tissue transglutaminase, the ϒcarboxamide of the glutamyl residue on the Biotin-
pepT26 is incorporated into the amine substrate to form a biotinylated-Isopeptide bond. The 
quantity of biotin incorporated is related to the TG2 activity, and is revealed by a peroxidase 
colourimetric reaction measured at 450 nm. Samples for the assay were prepared according 
to the manufacturer's protocol, 150 μl of 1X wash buffer was dispensed in each well and 
incubated for 15 mins at 370C. After 15 mins, the wash buffer was removed and replaced with 
50 μL of cold assay mixture, while in the negative control, 10 μL of EDTA were dispensed. 
Then, 50μL of cold protein sample was added to the test wells and incubated for 30 mins at 
370C with gentle shaking at intervals of 5 minutes. At the end of the incubation period, the 
wells were washed once with 200 μL of wash buffer, then washed again with 200 μL of 0.1M 
NaOH. Wells were subsequently washed twice with 200 μL of 1X Wash Buffer, and 100 μL of 
SAv-HRP solution was dispensed into each well and incubated at 370C for 15 minutes with 
mild agitation every 5 minutes. At the end of the incubation period, the wells were washed with 
200 μL of 1X Wash buffer, and 100 μL of HRP substrate was dispensed into each well and 
left at room temperature for 3 minutes. 100 μL of blocking reagent was dispensed into each 
well, and the optical density was measured at 450 nm using the automated microplate reader 
ELx 800 (BioTek UK). 
 62 
 
2.9.2 Fluorescent dansylcadaverine incorporation assay 
TG2 activity was also determined in situ using labelled monodansylcardavarine (DSV), a TG2 
fluorescent substrate which is easily detected using the BD accuri C6 flow cytometer at a 
wavelength of 533 nm. Following the protocol by D'Arcy 2017, 5 x105 cells were grown in a 
six-well plate, treated with retinoic acid and incubated between 24 and 72 hours. Media was 
then replaced with 50 ul of a 2 mM stock solution of dansylcadaverine. The activity of the 
enzyme was determined via FL-H relative fluorescent unit changes (RFU). Before cells were 
analysed, gating was performed to remove cell doublets and debris that could generate errors 
(figure 2.3).  
 
Figure 2.2: Gating limits for determining TG2 activity by cytometry  
The gating limits shows (a) cell debris was excluded by comparing side scatter area (SSC-A) against 
forward scatter height (FSC-A) (b) Single cells were identified by comparing forward scatter height 
(FSC-H) against forward scatter area (FSC-A). Comparing FSC-H/FSA-A gates out cell doublets. (c) 
From the single cells on the y-axis and FITC-H on the x-axis, a histogram was generated which 
measures the fluorescence of dansylcadaverine. The mean of FITC-H generated from each sample 
was compared to determine the enzyme activity between samples. 
 
2.10 TG2 inhibition by siRNA 
TG2 inhibition with specific anti-TG2 siRNA (AM16708, siRNA ID # 111472)  was performed 
using pre-designed siRNA 
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 (5’GGCCCGUUUUCCACUAAGATT3’, 3’UCUUAGUGGAAAACGGGCCTT) and transfection 
with Lipofectamine 2000 transfection reagent. Both reagents were obtained from Life 
Technologies UK. Cells were seeded into 96-well plates (1 x 104 per well) for viability assays 
and 6-well plates (1 x105 per well) for protein extraction, and allowed to adhere to plates. After 
24 hours, according to the manufacturers' guidelines, media was replaced by Opti-MEM™ 
medium, with reduced FBS because serum can affect transfection results, media was replaced 
with DMEM for another 24 hours before analysis was carried out.  The concentration of the 
reagents used for the silencing assay is shown in Table 2.4. 
Table 2.4: Concentration and volume of reagents used for silencing 
 Corning TC multiple well 
plates 
The total volume 
of media used 
Volume of 
lipofectamine 
The final concentration 
of siRNA  
1. 96-well plate 100 µl 0.3 µl 30 pmol 
2.  6-well plate 600 µl 5 µl 30 pmol 
 
Cells were incubated for 48 hours and then subjected to cell viability assay and Western 
blotting analysis. 
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2.11 Wound-healing ‘scratch’ assay 
A wound-healing assay (Liang et al., 2007) was performed by growing approximately 5 x 105 
cells in a 6-well plate for 24 hours. Media was replaced with fresh media and cells allowed to 
grow until they became confluent. 
 
Figure 2.4: Strategy for wound healing assay measurement 
(a) Scratch-made with a 10 µl pipette tip (b) width size was measured with the image j software. 
 
A ‘scratch’ or ‘wound’ was made on the cell monolayer, using a 10 µl pipette tip and images 
of cells were captured at different time points as the ‘scratch’ healed for 24hours, and the width 
was measured at each time point. Images were captured at 0.  2. 4. 8. 12, and 24 hours with 
the ZOE™ Fluorescent Cell Imager (Bio-Rad). The rate of cellular migration was computed by 
measuring ‘wound’ width in micrometres (µM) with the Image J software. 
2.12 Statistical analysis 
All data generated from the experiments were analysed with the GraphPad Prism software 
version 7.0. Results analysed were from three or more independent experiments.  
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Chapter 3: Optimisation of methods 
 
3.1 Use of HepG2 cells as a positive control 
The ability to reproduce data obtained by previous colleagues in the laboratory helped to 
develop and optimise the techniques needed for investigating TG2 expression. Since 
hepatocarcinoma (HepG2) cells have previously been shown to express high TG2 levels, they 
were considered a suitable cell line for optimising the techniques that would subsequently be 
applied in this research. 
3.2 Establishment of IC50 of HepG2 cells to cisplatin 
 
The HepG2 cell line was treated with an increasing series of concentrations of cisplatin for 24 
hours to determine the inhibitory concentration (IC50). This was done to establish the 
concentration of cisplatin required to induce cell death and was subsequently compared with 
the IC50 determined for the MCF-7 cells (fig 4.2). 
 
Figure 3.1: Cytotoxicity of cisplatin to HepG2 cells 
Cytotoxicity of cisplatin to HepG2 cells determined with the CCK assay, following 24 hours incubation.  
Data is expressed as mean ±SEM represent from at least three independent experiments. 
 
From fig 3.1, the IC50 of cisplatin on the HepG2 cells was calculated to be 8 µM indicating the 
concentration of cisplatin required to induce 50% cell death. Thus, to develop resistant cells, 
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wild type cells were subsequently grown in 8 µM of cisplatin for 24 hours, media replaced with 
fresh media without cisplatin, and the cells allowed to grow until they attained confluency (see 
section 2.3). This process was repeated, and the IC50 of the resistant cells was determined, to 
established resistance to cisplatin. The IC50 of the resistant phenotype was then compared 
with that of the wild type cells. The resistant cells were subsequently stored in liquid nitrogen 
(section 2.4).  
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Cell viability assay of cisplatin-resistant HepG2 cells  
Cytotoxicity of cisplatin on the resistant HepG2 cells determined with the CCK-8 assay after 24hours. 
Data is expressed as mean ±SEM represent from at least three independent experiments. 
 
The inhibitory concentration of the resistant phenotype was calculated to be 20 µM (fig 3.2), 
and thus, the cisplatin-resistant cells were seen to have developed a 2.3-fold increase in 
resistance to cisplatin.  
3.3 Effects of cisplatin on TG2 protein expression 
After developing the resistant cells, the effect of cisplatin on TG2 expression was determined 
by Western blotting. Both wild type and resistant cells were exposed to a series of increasing 
concentrations of cisplatin for 24 hours. After the incubation period, total protein was extracted 
for analysis (see section 2.7). 
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Figure 3.3: Cisplatin reduces TG2 expression in HepG2 cells 
Western blot analysis of both sensitive and resistant cells treated with a series of increasing cisplatin 
concentration for 24 hours. Band 1: represents control for the wild type cells; band 2: ( control for 
resistant cells); band 3: (4 µM wild type); band 4: (4 µM resistant cells); band 5: (6 µM wild type); band 
6: (6 µM resistant cells); band 7: (8 µM wild type); band 8: (8 µM resistant cells); band 9: (16 µM wild 
type); band 10: (16 µM resistant cells). β-actin is used as a loading control. 
 
 
 
From figure 3.3, there is a generally reduced expression of the protein in both phenotypes, 
indicating that as the concentration of cisplatin increases, levels of TG2 decreases. This 
suggests that cisplatin has a regulatory effect on TG2 levels in cells. The expression of TG2-
L in both cell lines was higher than that of TG2-S, and also, there was more TG2-L expressed 
in the wild type cells than the resistant cells.  
 
3.4 Discussion  
 
Optimisation of methods and technique reduces costs and improves productivity and 
minimises waste of laboratory reagents. It is also a means of building up confidence and usage 
of laboratory operating procedures, reagent protocols and equipment usage. The result 
presented in this chapter conform to those of a previous study by Meshram et al., (2017) 
showing a reduction in TG2 expression mediated by cisplatin. The validated reagents were 
subsequently utilised for experimental procedures on models of breast cancer resistance. 
 
 
Key 
W- wild type  
R- resistant cells 
µM- cisplatin concentration  
 
 
 68 
 
Chapter 4: Development of a cisplatin-resistant breast cancer cell model 
 
 
4.0 Introduction 
The foundation of this study is the development of a drug-resistant breast cell model. Results 
in this chapter aim to confirm that the treated cells developed resistance to cisplatin. Cells 
were exposed to the chemotherapeutic drug cisplatin until they became resistant, as described 
in section 2.3. Cell viability and apoptosis were measured by spectrophotometry and flow 
cytometry, respectively, using the CCK-8 and Annexin-V assays.  
4.1 Establishment of IC50 of MCF-7 cells to cisplatin 
 Cells were incubated with an increasing series of cisplatin concentration(s) for 24 hours to 
determine the concentration of drug to inhibit 50% of cells from growing. Cell viability was 
determined by spectrophotometry with the CCK-8 assay. The inhibitory concentration (IC50) 
was computed from a dose-dependent response curve.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 1: CCK-8 assay of the viability of sensitive MCF-7 cells 
CCK-8 cell viability assay performed on wild type MCF-7 cells in response to cisplatin after 24 hours 
incubation. The data were computed and presented as mean ± SEM from at least three independent 
experiments. 
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Figure 4.1 shows the inhibitory concentration of cisplatin on MCF-7 cells to be 18 µM, which 
is the concentration of cisplatin needed to inhibit 50% of cells from growing.  
 
4.2 Effect of cisplatin on MCF-7 cells 
The characteristics and state of cells after exposure to cisplatin was determined by flow 
cytometry, as described in section 2.5, which confirms the result obtained in figure 4.1. 
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Figure 4. 2: Effect of cisplatin on MCF-7 cells  
Representative cytogram of cells treated with cisplatin. (a) SSC-A/FSCA to collect single cells, (b) gating 
to exclude cell debris and doublets (c) MCF-7 untreated control, (d) cisplatin-treated cells at 20 µM. 
Data are presented as mean ± SEM, and the histogram (e) shows the difference between the control 
and treated cells (± SEM) and significance is denoted by *** (0.0008), ** (0.0024) when analysed by the 
2-way ANOVA. 
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The control cytogram in figure 4.2 (c) shows that 86.0% of cells were healthy, 0.2 % were in 
the early apoptotic phase, 6.0 % were in the late apoptotic phase, while 7.4 % are necrotic. In 
the cisplatin-treated cells, there was considerable cytotoxicity; 48.5 % of cells were healthy, 
1.2 % were in the early apoptotic phase, 24.2 % were in the late apoptotic phase, while 26.1 
% of the cells were in the necrotic phase. The histogram (e) represents the statistical 
representation of the cytograms of both the control and cisplatin-treated cells.   
 
4.3 Establishment of IC50 of cisplatin-resistant MCF-7 cells  
To establish the resistant phenotype which is referred to as RMCF, wild type MCF-7 cells in 
the logarithmic growth phase were exposed to the inhibitory concentration of cisplatin (18 µM 
of cisplatin for 24 hours), which resulted in about 80% cell death.  Media was replaced with 
fresh media without cisplatin and cells were allowed to grow until they became approximately 
70% confluent. The procedure was repeated (section 2.3) until a population of cells were 
selected as resistant, and the inhibitory concentration was determined. 
 
 
 
 
 
 
 
 
 
 
Figure 4. 3: Inhibitory concentration of cisplatin-resistant cells  
Determination of the inhibitory concentration of RMCF after cisplatin treatment for 24 hours, with the 
CCK- 8 assay. The data were computed and presented as mean ± SEM from at least three independent 
experiments. 
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The result in figure 4.3 illustrates that the concentration of cisplatin needed to induce cell death 
is 35 µM. When compared with the wild type cells (fig 4.1), the resistant cells were found to 
have developed a two-fold increased resistance to cisplatin.  
 
4.4 Effect of cisplatin on resistant cells’ profile 
 
Characterisation of RMCF-7 cells after cisplatin treatment was performed by flow cytometry, 
to investigate what percentages of the cells were still in a healthy state when compared with 
the wild type cells treated with cisplatin. Resistant cells were treated with 18 µM of cisplatin 
(inhibitory concentration of cisplatin) and incubated for 24 hours like the wild type cells. After 
incubation, cells were prepared for flow cytometry, as described in section 2.5. 
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Figure 4. 4: Apoptosis analysis of cisplatin-resistant cells 
Representative cytogram of resistant cells treated with cisplatin. (a) SSC-A/FSCA to collect single cells, 
(b) gating to exclude cell debris and doublets Representative cytogram of (c) RMCF-7 control cells and 
(d) RMCF cells after treatment with cisplatin showing cells in the different stages of apoptosis. The 
histogram (e) represents the difference between the different groups from at least three independent 
experiments presented as mean ± SEM and analysed with the 2 way ANOVA. 
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The result in figure 4.4 shows that the cells have developed resistance to cisplatin and 
confirms the cytotoxicity result in figure 4.3. Though there was a reduction between the RMCF 
control (85.2% healthy cells) and resistant cells (71.3% healthy cells), the difference was not 
statistically significant.   
4.5 Wound-healing assay on wild type and cisplatin-resistant MCF-7 cells. 
Migration of cells, also referred to as metastasis, is one of the characteristics of cancer cells, 
which is increased in drug-resistant cells. The assay was performed to determine the 
characterisation of the drug-resistant cell line developed for this research work.  
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Figure 4. 5: Scratch assay on wild type and resistant MCF-7 cells  
Representative pictographs (a) of wound-healing assay taken with the ZOETM Fluorescent Cell Imager 
to compare time for wound healing between wild type and resistant cells. The line graph (b) compares 
the distance (µM) covered between the wild type and resistant cells. Data are presented as mean ± 
SEM from at least three independent experiments. The difference between the wild type and resistance 
cells was statistically significant, and **** denotes significance (<0.0001) when analysed by the 2-way 
ANOVA. 
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Figure 4.5 shows drug-resistant cells migrating after 2 hours and that the ‘wound’ become 
covered after 24 hours, whereas the ‘wound’ was not closed up by the wild type cells after 24 
hours. The distance (µm) migrated was measured with the Image J software, and images 
acquired shows the resistant cells closed the  “scratch” created faster than the sensitive cells. 
Image scale was set at 100 µm, representing the level of magnification.  
4.6 Morphology of wild type and resistant cells  
 
Images of the wild type and resistant cells were captured with the ZOETM Fluorescent Cell 
Imager (Bio-Rad), and the morphologies were compared.  
 
 
 
Figure 4. 6: Morphology of wild-type and resistant cells  
Images of wild-type and resistant cells captured with the ZOE™ Fluorescent Cell Imager. The scale 
bar was set at 100 µm. Figure (a) represents the wild type cells, while (b) represents the resistant cells.  
 
 
 
 Morphologically, figure 4.6 shows the wild type cells are medium in size and quite consistent 
in shape while the resistant cells have a variety of irregular shapes. Some appear rounder and 
amoeboid exhibiting pseudopodia-like features. Dimensions of both wild type and cisplatin-
resistant cells were compared by flow cytometry where the forward scatter (FSC) intensity is 
proportional to the diameter of the cell (see section 2.5).  Smaller cells elicit a low FSC while 
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large cells have a high FSC (see figure 4.7). The result shows that cisplatin-resistant cells had 
increased FSC-A/SSC-A than the wild type cell. 
 
 
 
 
 
 
 
 
 
Figure 4. 7: Comparison of wild type cell and cisplatin-resistant cell sizes. 
Comparison of the forward scatter values between wild type MCF-7 cells and cisplatin-resistant cells 
by flow cytometry. The result is presented from the mean of at least four independent experiments ± 
SEM and significance denoted by * (0.0332) when analysed with the 2 way ANOVA. 
 
 
 
4.7 Determination of TG2 RNA expression levels 
 
For the determination of RNA expression levels, cells were prepared as described in section 
2.8. Cells were grown until they were about 70-80% confluent, and RNA extracted from 3 x106 
cells from each of the wild type and resistant cell lines.  
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Figure 4. 8: TG2 mRNA levels in wild type and cisplatin-resistant MCF-7  
Levels of mRNA were quantified using RT-PCR Roche LightCycler. Results are presented as mean ± 
SEM from at least three independent experiments and significance denoted by the p-value of 0.0061 
when analysed by the 2-way ANOVA. 
 
Figure 4.8 reveals higher mRNA levels of both TG2-L and TG2-S in the resistant phenotype 
compared to the wild type cells. The difference of TG2-L between the wild type and resistant 
phenotype was significant. The difference in TG2-S levels was not statistically significant 
though there was an increase.  
 
. 
4.8 Determination of TG2 protein expression levels in wild type and drug-resistant 
MCF-7 cells.  
Following the development of the resistant cell lines, TG2 protein expression was determined 
to confirm whether the levels of the enzyme are increased in the chemoresistant cell line in 
comparison with the wild type.  
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Figure 4. 9: TG2 protein expression in wild type and cisplatin-resistant cells  
TG2 levels in wild type and resistant cells determined by Western blotting. (a) representative Western 
blot while the histograms represent band quantification for (b) the long-form and (c) the short form of 
the protein. The result is presented as mean ± SEM from at least three independent experiments and 
significance denoted by ** with a p-value of 0.0035 when analysed with the Student t-test. 
 
  
From figure 4.9a, the blot shows that both TG2-L and TG2-S levels are elevated in the 
cisplatin-resistant cells as compared with the wild type, but the elevation of TG2-L levels is 
higher than the elevation of TG2-S.  
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4.9 Determination of TG2 enzyme activity  
The activity of the enzyme was determined with the specific tissue transglutaminase 
microassay kit (see section 2.9.1).  
 
Figure 4. 10: Enzyme activity determination 
Specific TG2 enzyme activity was determined with the COV-TG2 kit by spectrophotometry, in wild type 
MCF-7 cells and cisplatin-resistant cells. The result is presented as mean ± SEM from at least three 
independent experiments, and significance is denoted by the p-value of ˃ 0.0041 (**) when analysed 
with the Student t-test.  
 
 
Figure 4.10 reveals a higher enzyme activity in the resistant cells when compared to the wild 
type cells. The enzyme activity was analysed by flow cytometry to correlate the fact that the 
cisplatin-resistant cells have altered morphological changes when compared to the wild type 
cells (figure 4.7). However, the increased enzymatic activity was not due to the morphological 
differences (see figure  4.11). 
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Figure 4. 11: Enzyme activity by flow cytometry 
Cadaverine fluorescence (FITC-H) and forward scatter (FSC-A) between wild type MCF-7  and 
cisplatin-resistant cells. The results were computed from the mean of at least three independent 
experiments (±SEM), and the difference was not statistically significant when analysed with the Student 
t-test. 
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4.10 Discussion 
 
Developing a drug-resistant cell model helps in studying mechanisms involved in the 
development of resistance to chemotherapeutic drugs and how to overcome drug resistance. 
A cisplatin-resistant MCF-7 cell line was developed, which had an altered phenotype from the 
wild type. The resistant cells' response to cisplatin was different from that of the wild type cell. 
Morphologically, resistant cells also had varieties of shapes conforming with previously 
published images (Pogribny et al., 2010; Wang et al., 2013; Li et al., 2013). 
TG2-L mRNA expression was increased in the resistant cells, compared to wild type, while 
there was an elevated TG2-L protein level in the resistant cells which supports the theory that 
the long-form is involved in cell survival and drug resistance. The finding shows that there are 
Increased levels of TG2 in the resistant cells, which is consistent with findings from earlier 
studies that resistant cells express higher levels of the protein (Mangala et al., 2005; Herman 
et al., 2006; Eckert et al., 2015). 
The IC50 on MCF-7 cells in this study, which is (18 µM), did not conform to results obtained 
from other studies, except that by Nikolaus et al.,(2018) (Table 4.1). The difference(s) evident 
are probably due to passage number and concentration of cisplatin used on cells. In this study, 
a stock concentration of 2 mM was used (Section 2.0). 
Table 4.1: IC50 values in MCF-7 cells from other studies 
Reference IC50                                                              Method used
 
Suberu et al., 2014                                 5.25 µM                               MTT 
Yuwan et al., 2016                                 49.54 µM                              MTT 
Herrera et al., 2018                                40 µM                                   MTT 
H Nikolaus et al., 2018                           20 µM                                  MTT 
Hernandez-Valencia et al., 2018            4.7 µM                                 MTT 
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Results from this chapter demonstrate that the RMCF-7 cells have developed resistance to 
cisplatin. Differences in the biological characteristics of the resistant cells, as compared to the 
parental cells, such as being present in a variety of shapes foster wound healing, and 
increased TG2 levels are indicative of a resistant phenotype. The resistant cells also appear 
to lack the cell-to-cell adhesion of wild type cells; they exhibit spindle-like shapes and 
demonstrate the presence of pseudopodia (figure 4.8). Results from this study conform to the 
previous studies (Han et al., 2014; Wen et al., 2009) which suggest that morphological 
changes may help cisplatin-resistant cells proliferate after cisplatin therapy.  
The wound-healing assay is based on observation(s) of cells on the periphery of the scratch, 
which move to close it up until new cell-to-cell links have established. Resistant cells are seen 
to exhibit increased cellular invasion and migration; these properties are seen in the cisplatin-
resistant cells, while the wild type did not display such properties. 
The elevated protein expression of TG2 observed in the resistant cells conforms with the 
hypothesis that resistant cells express high levels of the protein. Increased TG2 expression 
has been observed in different tumours and also from metastatic sites such as pancreatic 
carcinoma (Verma et al., 2006), breast carcinoma (Mehta et al.,; 2004), Mehta., 1994), ovarian 
cancer (Sarpathy et al., 2007), Liver carcinoma (Meshram et al., 2017), skin cancer (Fok et 
al., 2006).   
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Chapter 5: Effect of retinoic acid-induced TG2 expression on cisplatin 
chemoresistance 
 
 
5.0 Introduction  
Retinoic acid (RA), a metabolite derived from vitamin A, is involved in different cellular 
functions such as foetal development, cell differentiation and proliferation (Kastne et al.,1995; 
Means et al., 1995). It has been shown to induce TG2 expression in different cell types such 
as macrophages (Chiocca et al., 1988), rat hepatocytes (Placentinni et al., 1988) and human 
hepatocarcinoma cells (Meshram et al., 2017). 
From the preceding chapter, it has been established that TG2 is elevated in the cisplatin-
resistant cell model. The objective of this chapter is to determine the degree of involvement of 
TG2 in cells’ resistance development. In order to establish this, both wild type and resistant 
cells were induced to increase expression of TG2 with retinoic acid, and the effect of the 
increased level of TG2 on cisplatin sensitivity was investigated.  
For the experiments in this chapter, cells exposed to retinoic acid for 72 hours are denoted as 
retinoic acid pre-treated cells - wild type (RAPC-WT) and the cisplatin-resistant cells (RAPC-
CR). The cisplatin sensitivity of both is compared to the wild type cells (untreated cells 
(control). 
5.1 Effect of retinoic acid on cell viability  
MCF-7 cells were treated with increasing series of concentrations (0-20 µM) of retinoic acid 
for 72 hours to generate the RAPC-WT cells. The effect of retinoic acid on the viability of the 
cells was determined using the MTT assay.  
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Figure 5. 1: Effect of retinoic acid on the viability of RAPC-WT cells 
Cell viability of MCF-7 cells treated with retinoic acid for 72 hours determined with the MTT assay. 
The result is presented as means ± SEM computed from at least three independent experiments. 
 
Figure 5.1 reveals that the concentrations of retinoic acid used were not toxic, and the RAPC-
WT cells remained viable over the entire 0-20 µM concentration range.   
 
5.2 Apoptosis analysis of RAPC-WT cells 
Further confirmation of the state and viability of cells was determined by annexin V assay.        
In 6-well plates, 2 X 105 of wild type MCF-7 cells were seeded and allowed to adhere to the 
plates for 24 hours and media replaced with fresh media containing 10 µl and 20µl of retinoic 
acid. Both treated cells and the untreated cells (control) were incubated at standard culture 
conditions for 72 hours.  After 72 hours incubation, both treated and untreated control cells 
were harvested and prepared for flow cytometry analysis as described in section 2.5.  
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Figure 5. 2: Flow cytometry analysis of cells treated with retinoic acid for 72 hours  
Apoptosis analysis of cells treated with 10µM and 20µM retinoic acid. (a) SSC-A/FSCA to collect single 
cells, (b) gating to exclude cell debris and doublets. Representative cytogram of RAPC-WT cells 
showing (c) control (untreated wild type MCF-7), (d) MCF-7 cells + 10 µM RA (e) MCF-7 cells + 20µM 
RA. The histogram (f) illustrates the proportions of the different cell populations expressed in 
percentages. The result is presented as mean ± SEM from at least three independent experiments. 
Statistically, the difference between control and treated was not statistically significant when analysed 
with the 2 way ANOVA. 
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Again, retinol concentration had no effect on cell viability over the 0-20 µM concentration range 
tested. More than 80% of cells treated with 10 and 20 µM RA concentration in (b) and (c) 
respectively remained healthy and comparable with the control (a). The population of cells in 
the other three quadrants of the cytograms are negligible, and the result shows the 
concentration of RA tolerable by cells, confirming the viability assay in figure 5.1.    
5.3 Effect of retinoic acid concentration on TG2 expression in RAPC-WT 
Following the incubation with RA for 72 hours, total protein was extracted and analysed for 
TG2 expression by Western blotting, to determine the pattern and level of TG2 isoform 
increase after incubation (see section 2.6 and 2.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 3: Retinoic acid induces TG2 expression in MCF-7 cells 
Representative Western blot (a) wild type cells treated with 10 µM and 20 µM retinoic acid for 72 hours. 
The histogram (b) quantifies both TG2-L and TG2-S levels and the result is presented as means ± SEM 
from at least three independent experiments and analysed with the 2 way ANOVA. Significance is 
denoted by *(0.0242) and **(0.0077). 
 
 
The Western blot result in figure 5.3 shows that RA induced TG2 expression in the cells when 
the untreated control is compared to the retinoic acid-treated cells. There was a general 
increase in TG2 levels in both RA concentrations but a more significant induction of TG2-L 
Key-  
0 µM - Untreated control 
10 µM- Retinoic acid concentration  
20 µM- Retinoic acid concentration  
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compared to TG2-S. TG2-S levels appear to be similar between the control and treated cells, 
and the relative increase of TG2-L to TG2-S is in a 6:1 ratio (TG2-L increase was 6x more 
than TG2-S). The relative ratio was calculated by dividing TG2 Level from the 20 µM RA 
treated cells by the untreated control. 
 
5.4 TG2 expression over 72 hours in RAPC-WT cells.  
To determine the time course of the induction of TG2 expression, cells were incubated with 
retinoic acid for 24, 48 and 72 hours. Briefly, cells were seeded, treated with retinoic acid and 
harvested over different time points. As in section 5.4, the protein was extracted, and TG2 
expression determined by Western blotting (see section 2.6 and 2.7). 
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Figure 5. 4: TG2 pattern of expression in RAPC-WT over 72 hours incubation 
(a) Representative Western blot showing induction of TG2 after retinoic acid treatment over 72 hours. 
The histograms quantify the bands after (b) 24 hours (c) 48 hours (d) 72 hours. β-actin was used as a 
loading control, and the difference in the levels of TG2-L was statistically significant when analysed with 
the 2-way ANOVA. Significance is denoted by * (0.0283) and ***(0.0003), and the results are presented 
as means ± SEM from at least three independent experiments. 
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Overall, over the 72 hours, there was no significant increase in TG2 levels in the untreated 
controls, but with the retinoic acid-treated cells, TG2-L increase is evident after 24 hours, with 
a further increase(s) after 48 hours and 72 hours. Conversely, TG2-S expression remained 
the same between the untreated control and treated cells after 48 hours, but an increase was 
observed after 72 hours. 
 
5.5 Effect of retinoic acid on TG2 activity in RAPC-WT cells determined with 
fluorescent monodansylcardavarine 
 
Briefly, 2 x105 cells were grown in media with 10 and 20 µM retinoic acid for 24 and 72 hours. 
The activity of the enzyme was determined by flow cytometry using labelled 
monodansylcardavarine as the TG2 substrate (section 2.9.2). TG2 incorporation of the 
fluorescent substrate, monodansylcardavarine into cells is detected at a wavelength of 533 
nm, and the effect on TG2 activity is displayed as column graphs. 
 
 
 
 
 
 
 
 
 
 
Figure 5. 5: Effect of retinoic acid treatment on TG2 enzyme activity, measured by flow 
cytometry 
The enzymatic activity of RAPC-WT cells determined after 24 and 72 hours by flow cytometry using 
labelled monodansylcardavarine. The figure compares TG2 activity after 24, and 72 hours from three 
different experiments were statistically significant when analysed with the 2 way ANOVA, and the 
statistical difference is denoted by * ( 0.0347). The results are presented as means ± SEM from at least 
three independent experiments.  
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Overall, the histogram in fig 5.5 suggests that the activity of the enzyme is time and RA 
concentration-dependent and could be related to the increased TG2 levels, as seen in figures 
5.3 and figure 5.4. As TG2 level increased, the activity was also seen to be increased. The 
limitation of this assay is the inability to determine the activity of the differential isoforms (TG2-
L and TG2-S). 
 
5.6 Effect of cisplatin toxicity on RAPC-WT cells 
To assess the effect of increased TG2 levels on cell’s sensitivity to cisplatin, RAPC-WT cells 
were treated with cisplatin. Briefly, cells were seeded in a 96-well plate, treated with retinoic 
acid for 72 hours, media was replaced with media containing an increasing series of 
concentration of cisplatin, and incubated for 24 hours. After the incubation period, the inhibitory 
concentration was determined with the MTT assay (section 2.2.2). 
 
 
Figure 5. 6: Effect of cisplatin on retinoic acid pre-treated cells - wild type cells  
Cytotoxicity of cisplatin on the viability of wild type cells after retinoic acid pre-treatment for 72 hours 
determined by MTT assay. The results are presented as means ± SEM from at least three independent 
experiments.  
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The viability graph in figure 5.6 shows that the treated cells (black and red curves), unlike the 
control, were relatively insensitive to cisplatin toxicity, which implies that treatment with RA 
reduced MCF-7 cells’ sensitivity to cisplatin at the previous IC50 of 18 µM. 
5.7 Apoptosis analysis of RAPC-WT cells following cisplatin treatment 
 
RAPC-WT cells were exposed to cisplatin (18 µM) at the IC50, to determine whether 50% of 
the cells will still be inhibited from growth.  As previously described in section 2.4, cells were 
analysed by flow cytometry, and the apoptosis analysis (figure 5.8) confirmed the MTT assay 
(see figure 5.6). 
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Figure 5. 7: Flow cytometry analysis of retinoic acid pre-treated wild type cells (RAPC-WT) 
exposed to cisplatin.  
Representative cytogram of wild type cells pre-treated with retinoic acid (a) SSC-A/FSCA to collect 
single cells, (b) gating to exclude cell debris and doublets. Representative cytogram of RAPC-WT cells 
after cisplatin treatment showing the cytograms of the cells in the different treatment groups 
characterised into healthy, early apoptotic, late apoptotic and necrotic. (c) Untreated control, (d) cells 
treated with 18 µl cisplatin only (e) RTPC-WT + 10 µM RA + 18 µM cisplatin, (f) RAPC-WT + 20 µM RA  
+ 18 µM cisplatin. The results were analysed with the 2 way ANOVA and presented as means ± SEM 
from at least three independent experiments. The histogram compares the mean of the different groups, 
and significance is denoted by **** (<0.0001).  
(f) 
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Figure 5.7 shows that 87% of cells were healthy in the untreated control cytogram, and after 
RA and cisplatin, there were still over 70% healthy cells, suggesting that the retinoic acid pre-
treated cells had reduced sensitivity to cisplatin. Cells pre-treated with retinoic acid had 
reduced sensitivity to the IC50 of cisplatin toxicity when compared to the untreated control (d). 
5.8 Effect of cisplatin on TG2 expression in RAPC-WT cells. 
The relationship between TG2 and cellular development of cisplatin resistance was 
investigated by exposing RAPC-WT cells to 18 µM of cisplatin ( which is the IC50 of control 
cells). Cells were then incubated for a further 24 hours to determine the pattern of TG2 
expression.  
 
 
 
 
 
 
 
 
 
Figure 5. 8: Retinoic acid increases TG2-L expression levels in the presence of cisplatin 
Western blot (a) analysis RAPC-WT cells exposed to 18 µM cisplatin with two controls: MCF-7 cells (0) 
and MCF-7 cells + cisplatin (0+). β-actin was used as a loading control, and the histograms quantify (b) 
TG2-L (c) TG2-S levels and presented as means ± SEM from at least three independent. Significance 
is denoted by *(0.0241), ** and (0.0086) when analysed with the 2 way ANOVA.  
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 From the blot shown in figure 5.8a, when the untreated control (0) is compared with the other 
groups, cisplatin reduced TG2-L levels in the 0+ control, with a much greater effect on TG2-L 
than TG2-S. The opposite pattern was observed in the RAPC-WT cells, where TG2-L levels 
appear to be maintained, or slightly increased, at both retinoic acid concentrations, but when 
compared to the cisplatin control (0+), there is a significant increase of TG2-L levels. Overall, 
there is a decrease of TG2-S expression between the untreated control (0) and the treated 
cells. TG2-S levels in the cisplatin-treated control (0+) were reduced to approximately half of 
those in the untreated control, while in the retinoic acid-treated cells; the reduction was 
profound. The ratio of TG2-L to TG2-S after retinoic acid and cisplatin treatment in RAPC-WT 
is in a 9:1 TG2-L to TG2-S ratio.  
5.9 Effect of cisplatin  on RAPC-CR cells 
 
To assess the effect of increased TG2 levels on cell’s sensitivity to cisplatin, RAPC-CR cells 
were treated with cisplatin. Briefly, cells were seeded in a 96-well plate, treated with retinoic 
acid for 72 hours, media was replaced with media containing an increasing series of 
concentration of cisplatin, and incubated for 24 hours. After the incubation period, the inhibitory 
concentration was determined with the MTT assay (section 2.2.2). 
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Figure 5. 9: Effect of cisplatin on RAPC-CR cells 
Cytotoxicity of cisplatin on cisplatin-resistant cells after retinoic acid pre-treatment for 72 hours 
determined by MTT assay. The results are presented as means ± SEM from at least three independent 
experiments. 
 
 
The viability graph in figure 5.9 shows that the retinoic acid-treated cells (black curve), unlike 
the control (red curve), were less sensitive to cisplatin toxicity, which implies that treatment 
with RA  reduced RMCF-7 cells’ sensitivity to cisplatin at the previous IC50 of 35 µM. 
 
5.10 Determination of TG2 levels in retinoic acid pre-treated resistant (RAPC-CR) 
MCF-7 cells  
Equal numbers (2 x 105) of cisplatin-resistant cells were incubated with 10 µM or 20 µM 
concentrations of retinoic acid, respectively and incubated for 24, 48 or 72 hours. Cells were 
harvested after the incubation period and total protein extracted for Western blotting as 
described in section 2.6 and 2.7.  
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Figure 5. 10: TG2 expression is induced by retinoic acid in retinoic acid pre-treated resistant 
(RAPC-CR) cells 
Western blot (a) of RAPC-CR cells after TG2 was induced with retinoic acid for 24, 48 and 72 hours. Β-
actin was used as the loading control for normalization. The histograms represent band quantifications 
after 24 hours (b), 48 hours (c) and 72 hours (d). All data were analysed by the 2-way ANOVA and 
significance is symbolised by p values * (0.0100), ** (0.0037) and *** (0.0010). The results are presented 
as means ± SEM from at least three independent experiments. 
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Generally, the blot shows that TG2 induction is concentration and time-dependent as in the 
wild type cells. Over the 72 hours, there was an increase in TG2 levels in the untreated control, 
but a more profound increase was seen in the retinoic acid-treated cells. Conversely, TG2-S 
expression increased after 48 hours and was maintained after 72 hours. 
5.11 Effect of cisplatin on retinoic acid pre-treated resistant cells (RAPC-CR)    
To determine the effect of retinoic acid on cisplatin toxicity, 5 x105  cisplatin-resistant cells were 
treated with 10 µM or 20 µM of RA in a 6-well plate for 72 hours. After incubation, media was 
removed and replaced with fresh media containing 35 µM of cisplatin (IC50 of resistant cells ) 
and incubated for a further 24 hours.  At the end of the incubation period, total protein was 
extracted from the cells and analysed for TG2 expression by Western blotting and β-actin was 
used as the loading control. 
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Figure 5. 11: Effect of cisplatin on TG2 expression in RAPC-CR cells 
Western blot of RAPC-CR cells (a) showing the levels of both isoforms to 35 µM cisplatin treatment. 
The histogram represents band quantifications from three independent experiments for (b)TG2-L (c), 
TG2-S  and (d) comparison between both isoforms. Normalisation was with β-actin, and the results are 
presented as means ± SEM from at least three independent experiments and analysed with the 2 way 
ANOVA.  Statistical significance is denoted * (0.0448). ** (0.0013) and *** (0.0002). 
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Overall, the blot in figure 5.11 shows an increase in TG2-L levels in the untreated control that 
was also seen in the retinoic acid, pre-treated cells with a slight reduction in the cisplatin-
resistant control cells (R0+). The opposite was observed in TG2-S levels as there was a 
decrease in the cisplatin-resistant control cells (R0+) with a further reduction in the retinoic 
acid pre-treated cells when compared to the untreated cisplatin-resistant control cells (R0). 
TG2-L/TG2-S ratio in the resistant cells was also similar to the wild type suggesting that the 
increased level of the long-form could be responsible for the reduced efficiency of cisplatin in 
the cells.  
5.12 Comparison of TG2 activity in RAPC-WT and RAPC-CR cells with the TG2 COV 
assay kit 
The enzymatic activity of both retinoic acid-treated cell types was determined with the TG2 
COV assay kit following the protocol described in section 2.9.1 to access the difference after 
cisplatin treatment. Both wild and cisplatin-resistant MCF-7 cells were exposed to the IC50 (18 µM 
and 35 µM) of cisplatin for 24 hours, total protein was extracted, and the activity determined. 
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Figure 5. 12: Enzyme activity of RAPC-WT and RAPC-CR cells after cisplatin treatment 
 
TG2 activity determined with the TG2 COV assay kit of (a) RAPC-WT and (b) cisplatin-resistant cells 
Comparison between wild type and resistant cells is illustrated in (c). Statistical significance is denoted 
by   ** (0.0048), *** (0.0002).and **** (<0.0001). The results are presented as means ± SEM from at 
least three independent experiments and analysed with the 2-way ANOVA. 
 
There was no significant increase in TG2 activity in the RAPC-WT cells after cisplatin 
treatment. Almost the same pattern is mirrored in the RAPC-CR cells except at the 20 µM 
concentration, where the activity doubled the wild type cells.   
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5.14 Discussion  
 
In general, TG2 expression increase correlated with chemoresistance and the results from 
this chapter show TG2-L as the isoform most increased with an associated reduction in the 
sensitivity to cisplatin. Retinoic acid was an effective TG2 inducer in this study which is 
consistent with results from previous studies in HeLa cells (Singh et al., 1996); cervical 
sympathetic ganglia (Ando et al., 1995); and Chondrocytes (Lee et al., 2010).  
A variation in the long and short form of the protein (control) is observed, and more studies 
need to be done with regards to tissue culture plate size, cell density and the effect on protein 
expression in in-vitro assays. 
 
 
 
 
. 
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Chapter 6: TG2 inhibition studies using cystamine 
 
6.0 Introduction  
Results from the preceding chapter show that the increased expression of TG2 and particularly 
TG2-L correlated with the wild type cells being less sensitive to cisplatin while the resistant 
cells become more chemoresistant. It also gives more credence to the hypothesis that TG2-L 
supports cell survival and is involved in the development of resistance. Experiments were 
designed to determine the effect of TG2 inhibition on the sensitivity of MCF-7  cells to cisplatin 
and to determine the isoform inhibited by cystamine. TG2 was inhibited in both wild and 
resistant cell types with cystamine and further exposed to cisplatin.  
Both wild type and cisplatin-resistant cell types were exposed to cystamine for 24 hours 
(section 2.0) to inhibit TG2, and the TG2-inhibited cells were further exposed to cisplatin for 
another 24 hours.  The toxicity of cystamine on the cells was first accessed to ensure a 
tolerable non-toxic concentration were used. Then, the effect on TG2 expression was detected 
by Western blotting, and the effect on cisplatin toxicity was determined. A freshly-made 2 mM 
cystamine stock concentration was used for each study, and results are computed from at 
least three independent experiments. 
6.1. Effect of cystamine on cell viability  
The toxicity of cystamine was determined by treating cells with an increasing series of 
cystamine concentrations.  
 
 104 
 
0 20 40 60 80 100
0
20
40
60
80
100
Cystamine conc (M)
c
e
ll
 v
ia
b
il
it
y
 %
 
 
Figure 6.1: Effect of cystamine on wild type cell viability 
 
Viability of wild type MCF-7 cells treated with cystamine for 24 hours determined with the MTT assay.  
The results are presented as means ± SEM from at least three independent experiments, and cells are 
seen to be viable at the concentrations tested.   
 
 
Fig 6.1 shows a concentration range of 0 –100 µM of cystamine was not toxic to the cells, with 
only a 10% loss of viability at 100 µM. Choosing a tolerable concentration for cells was 
essential to avoid cell death due to cystamine treatment. For this study, cells were, therefore, 
pre-treated with a 50 µM and 100 µM cystamine to inhibit TG2 activity , before cisplatin 
treatment. 
 
6.2 Determination of the viability of cystamine-treated cells with Annexin V assay 
To support the MTT assay results, the viability of the cells was also determined by the  Annexin 
V and propidium iodide analysis. This assay assesses the numbers of cells that have 
undergone apoptosis. Briefly,5 x 105 cells were treated with 50 µM or 100 µM cystamine for 
24 hours. After 24 hours incubation, the cells were harvested and prepared for flow cytometry 
analysis, as described in section 2.5.    
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Figure 6.2:  Flow cytometry Annexin V analysis of cells treated with cystamine  
Representative cytogram of cystamine-treated cells analysed by flow cytometry to determine their 
viability. (a) SSC-A/FSCA to collect single events (b) gating to exclude cell debris and doublets 
represents the untreated control cells, (c) MCF-7 control cells (d) cells treated with 50 µM cystamine, 
(d) cells treated with 100 µM cystamine and a (d) histogram showing the viability of cells in percentages. 
The results are presented as means ± SEM from at least three independent experiments, and the 
difference was not statistically significant with the 2 way ANOVA. 
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The cytogram in figure 6.2 shows the population of cells at different stages of apoptosis. In 
the untreated control cells (a) 94.1% were healthy, and after 50 µM cystamine treatment, 
93.2% were still healthy, with 92.4% of cells remaining healthy after 100 µM cystamine 
treatment. Overall, the results show that cystamine treatment had little effect on cell viability, 
supporting the result of the MTT assay shown in figure 6.1. 
 
 6.3 Effect of cystamine on TG2 levels in wild type MCF-7 cells.  
 
Following confirmation that 0-100 µM cystamine is tolerable to the cells, the effects on TG2 
expression were investigated by Western blotting. Briefly, 5 x105 wild type cells were seeded 
in 6-well plates and treated with 50 µM and 100 µM cystamine for 24 hours and protein 
extracted for the analysis as described, in sections 2.6 and 2.7. 
 
 
 
 
Figure 6.3: TG2 expression after treatment of wild type cells with cystamine 
Representative Western blot (a) analysis of MCF-7 cells exposed to cystamine for 24 hours and the 
histogram (b) quantify both TG2-L and TG2-S bands and presented as means ± SEM from at least 
three independent experiments and analysed with the 2-way ANOVA. Β-actin was used as a loading 
control. Statistical significance is denoted by * (0.0448).  
 
 
 
Overall, the Western blot in figure 6.4 does not show a profound decrease in TG2 levels, but 
there is a decrease in TG2-L expression in the cystamine-treated cells as compared to the 
control. In contrast, TG2-S expression is similar in the cystamine-treated cells with the control 
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and Increasing the incubation time with cystamine might yield more promising results and 
inhibit TG2-L levels more significantly.   
 
6.4 Effect of cisplatin on cystamine pre-treated MCF-7 cells. 
The cytotoxic effect of cisplatin was investigated after TG2 inhibition with cystamine to 
determine if cells will be sensitised to cisplatin at lower concentrations. Briefly, approximately 
5 x 105 cells were exposed to 50 µM and 100 µM cystamine for 24 hours, the media was 
replaced with fresh media containing increasing series of cisplatin concentration, and cells 
were re-incubated for a further 24 hours. Cell viability was determined with the MTT assay.  
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Figure 6.4:  Effect of cisplatin on cystamine pre-treated wild type cells  
Effect of cisplatin on cystamine-treated cells determined with the MTT assay. The line curves represent 
the different treatment groups, (orange line curve) cells treated with cisplatin only, cells treated with 50 
µM (black line curve) and 100 µM cystamine (blue line curve) The result is presented as means ± SEM 
from at least three independent experiments. The difference between the cisplatin treated cells and 
TG2 inhibited cells was statistically significant with a p value of 0.0015 when analysed with the 2 way 
ANOVA. 
 
 
 
Cystamine pre-treated cells 
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The graph shown in figure 6.4 illustrates the viability curves of cells after TG2 inhibition 
suggesting that the inhibition of TG2 before cisplatin treatment sensitises the cell into 
apoptosis at lower cisplatin concentration. The IC50 of the wild type cells was 18 µM (red curve) 
which reduced after TG2 inhibition to 5 µM (blue and black curve). Further validation of the 
cytotoxicity results in figure 6.4 was confirmed using two other controls.  In the first control, 
cells were treated with a combination of cisplatin and cystamine for 24 hours (figure 6.5), while 
in the second control, cells were exposed to cisplatin for 24 hours before cystamine treatment 
(figure 6.6). These controls were set up to confirm the effects of inhibiting TG2 activity first, 
before treatment with cisplatin.  
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Figure 6.5: Viability of wild type cells treated with a combination of cystamine and cisplatin  
Cytotoxicity of cisplatin in combination with cystamine on MCF-7 cells determined using the MTT assay.  
The line curves represent the different treatment groups, cells treated with cisplatin only, cells treated 
with 50 µM and cisplatin(black line curve) and 100 µM cystamine + cisplatin (blue line curve) The result 
is presented as means ± SEM from at least three independent experiments. The difference between 
the cisplatin treated cells and TG2 inhibited cells was statistically significant with a p value of 0.0055 
when analysed with the 2 way ANOVA. 
 
 
Figure 6.5 shows a reduction to 12 µM in the IC50 of cells that were treated with a combination 
of cystamine and cisplatin. In comparison, cells treated with cisplatin alone had an IC50 of 18 
µM. The results reveal that treatment with a combination of cisplatin and cystamine does not 
inhibit cell viability to the same degree as pre-treatment with cystamine (figure 6.4). 
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Figure 6.6: Viability of wild type cells pre-treated with cisplatin 
 
Cell viability of cisplatin pre-treated cells before cystamine treatment determined by the MTT assay. 
The line curves represent the different treatment groups cells treated with cisplatin only(red curve), cells 
pre-treated with cisplatin and 50 µM (black line curve) and 100 µM cystamine (blue line curve) The 
result is presented as means ± SEM from at least three independent experiments. The difference 
between the cisplatin treated cells and TG2 inhibited cells was statistically significant with a p value of 
0.0193 when analysed with the 2 way ANOVA. 
 
Exposure of cells to cisplatin before TG2 inhibition reduced the IC50 from 18 µM to 15 µM 
validating the result in figure 6.4 that inhibition of TG2 before cisplatin treatment significantly 
sensitises cells to cisplatin at lower concentrations than cystamine/cisplatin co-treatments.  
 
Table 6.1: Comparison of the inhibitory concentrations of the different treatments. 
Type of treatment  Inhibitory concentration  
Cisplatin only  18 µM 
Cystamine pre-treated + cisplatin    5 µM 
Cisplatin pre-treated + cystamine  15 µM 
Combination of cisplatin/cystamine 12 µM  
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 Table 6.1 summarises the inhibitory concentrations from the different cytotoxicity assays and 
suggests that inhibiting TG2 with cystamine sensitises cells to cisplatin. 
 
6.5 Flow cytometric analysis of the effect of cisplatin on wild type cells after TG2 
inhibition   
Wild type MCF-7 cells were stained with Annexin V to determine the percentages of cells 
undergoing apoptosis and confirm the result in figure 6.4. Briefly, 5 x 105 cells were grown in 
6 well plates, and TG2 was inhibited with 50 and 100 µM cystamine for 24 hours, and at the 
end of the incubation, the media was replaced with fresh media containing 18 µM of cisplatin 
(IC50 of cisplatin).  Cells were further incubated for another 24 hours and prepared for flow 
cytometry.  
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Figure 6.7: Effect of cisplatin on wild type cells after TG2 inhibition with cystamine. 
Representative cytogram of wild type cells treated with cisplatin after TG2 inhibition with cystamine (a) 
SSC-A/FSCA to collect single cells, (b) gating to exclude cell debris and doublets  (c) Untreated control; 
(d) cisplatin control(e) and (f), cystamine pre-treated cells. The histogram (g) represents the 
characterisation of the cells into healthy, early, late apoptotic and necrotic cells. The difference between 
treated and untreated are significant and symbolised by * (0.0448), ** (0.0013) and **** (<0.0001) when 
analysed with the 2 way ANOVA. The results are presented as means ± SEM from at least three 
independent experiments.  
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Figure 6.7 shows that the percentage of healthy cells (a) in control was 83..2%, and after 
cisplatin-treatment, the percentage of healthy cells was reduced to 46.2%. With TG2 inhibition, 
there was a further reduction of healthy cells to 38.4% with 50 µM and 32.2% with 100 µM 
cystamine. The result confirms that TG2-inhibited cells entered into apoptosis more than the 
cisplatin-treated cells, supporting the MTT assay in figure 6. 4. 
6.6 Effect of cisplatin on TG2 expression in cystamine pre-treated cells.  
The effect of cisplatin on TG2 levels after inhibition with cystamine was investigated. Equal 
numbers of cystamine pre-treated cells (5 x 105) were exposed to cisplatin for 24 hours, and 
total protein was extracted and analysed by Western blotting (see section 2.6 and 2.7). 
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Figure 6.8: Western blot analysis of cystamine pre-treated MCF-7 cells treated with cisplatin.  
Representative Western blot of (a) cystamine pre-treated cells, showing TG2 levels after treatment with 
cisplatin for 24 hours. The histogram (b) represents TG2-L band quantification while (c) represents TG2-
S band quantification. The data is computed from at least three independent experiments and presented 
as means ± SEM. Statistical significance is denoted by *(0.0448), ** (0.0023) and *** (0.0007) when 
analysed with the 2 way ANOVA. 
 
The Western blot in figure 6.8 overall, shows a reduction in TG2 expression between the 
treated cells and the untreated control. There is a significant decrease in TG2 expression in 
cells where TG2 was inhibited as compared to cisplatin only treated cells.  TG2-L expression 
was observed to reduce as the concentration of cystamine increased, and cells treated with 
100 µM cystamine had lower TG2-L expression than cells treated with 50 µM cystamine. There 
was also a reduction in TG2-S expression, but that reduction was less significant than TG2-L.    
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6.7 Effect of cystamine on the viability of cisplatin-resistant MCF-7 cells 
Cisplatin-resistant MCF-7 cells were also pre-incubated with a series of increasing cystamine 
concentrations for 24 hours to compare the toxicity observed in the wild type cells.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9: Effect of cystamine on the viability of cisplatin-resistant cells 
The effect of cystamine on the viability of cisplatin-resistant cells was determined with the MTT assay. 
The result was computed from at least three independent experiments and presented as means ± SEM.   
 
 
 
Compared to the wild type cells, after 24-hour incubation, the cisplatin-resistant cells were still 
seen to be viable. The  0-100 µM cystamine concentration range was not detrimental to the 
cells.  
 
6.8 Effect of cystamine on TG2 levels in resistant cells 
After confirmation that 0-100 µMcystamine is tolerable, chemoresistant cells were treated with 
cystamine for 24 hours to determine the expression of TG2.  Equal numbers of cells (5 x 105) 
were seeded in a 6-well plate and treated with 50 µM or 100 µM of cystamine for 24 hours. 
After incubation, cells were harvested, and protein extracted for Western blotting (see section 
2.6 and 2.7).  
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Figure 6.10: Effect of cystamine on TG2 level in cisplatin-resistant cells 
Representative Western blot (a) of resistant cells after cystamine treatment for 24 hours, The histogram 
(b) represents total band quantification from three independent experiments, and the difference 
between the TG2-L and TG2-S levels was significant and denoted with * (0.0298). β-actin was used as 
the loading control. The data is computed from at least three independent experiments, analysed with 
the 2 way ANOVA and presented as means ± SEM.  
 
The Western blot in figure 6.10 shows a general reduction of TG2 expression in the treated 
as compared to the control cells. This follows a similar pattern to the wild type cells (figure 
6.4). With regards to the isoforms, as the levels of TG2-L is reduced in the TG2 inhibited cells, 
an increase is noticeable in TG2-S, especially after treatment with 100 µM cystamine. The 
profile of TG2 inhibition is time-dependent according to existing literature (Siegel and Khosla 
2007), perhaps increasing the pre-treatment with cystamine from 24 to 48 hours or even 72 
hours, might inhibit TG2-L significantly.  
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6.9 Cell viability of resistant cells after TG2 inhibition  
To determine the effect of TG2 inhibition of TG2 expression, cisplatin-resistant cells were pre-
treated with cystamine for 24 hours. Media was replaced with media containing a series of 
increasing concentrations of cisplatin and incubated for another 24 hours. The toxicity of 
cisplatin on the cells was then determined using the MTT assay (section 2.2.2). 
 
Figure 6.11: Cell viability of cystamine pre-treated chemoresistant cells exposed to cisplatin.  
Viability of cisplatin-resistant cells after TG2 inhibition determined using the MTT assay. (a) displays 
cells pre-treated with 50 µM cystamine before cisplatin treatment; (b)  cells pre-treated with 100 µM 
cystamine while (c) represents cells treated with cisplatin only. (d) shows combined viability from all 
groups. The data is computed from at least three independent experiments and presented as means ± 
SEM. 
 
 
There is a reduction in the IC50 of cells in which TG2 was inhibited by cystamine as compared 
to the control (cells treated with cisplatin alone). Figure 6.11a shows the viability of all treated 
groups, and the IC50 of cystamine-treated cells was reduced to 20 µM from 35 µM (control). 
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The results suggest that TG2 inhibition in the resistant cells sensitises the cells to cisplatin at 
lower concentrations. 
 
6.10 Effect of cystamine and cisplatin on TG2 level expression in resistant cells  
 
The results in figure 6.11 show that the inhibition of TG2 with cystamine reduced the IC50 of 
cisplatin, so the effect on TG2 expression was also determined. Like the wild type, the resistant 
cells were grown in the presence of cystamine for 24 hours to inhibit TG2, before being treated 
with cisplatin at the IC50 (35 µM) of the resistant cells, (figure 4.4). Cells were then harvested, 
and protein was extracted for Western blotting analysis (see section 2.6 and 2.7). 
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Figure 6.12:  Effect of cisplatin on TG2 expression in cystamine pre-treated cisplatin-resistant 
cells  
Representative Western blot (a) of TG2 expression in cystamine pre-treated cisplatin-resistant cells. 
The histogram represents the quantification of the bands from three independent experiments, (b) TG2-
L and (c) TG2-S. The data is computed from at least three independent experiments and presented as 
means ± SEM and analysed with the 2 way ANOVA. Significance is denoted by the p-value ** (0.0023). 
 
There is a general reduction of TG2 expression in the treated cells as compared to the control 
cells and decreased TG2-L levels when compared to TG2-S levels. The expression of TG2-L 
is seen to be further reduced in cells, where TG2 was inhibited with cystamine, and the 
expression decreased as the concentration of cystamine was increased.  This could be 
responsible for the reduction of the IC50 of the resistant cells from 35 µM to 20 µM, as shown 
in figure 6.11d.  
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6.11 Effect of cisplatin on resistant cells after TG2 inhibition  
 
To confirm the MTT assay (figure 6.11) and cytotoxicity of cisplatin on resistant cells after TG2 
inhibition (6.12), cells were stained with Annexin V and propidium iodide analysis, which sums 
the numbers of cells that have undergone cell death (section 2.5). Briefly, cells were pre-
treated with 50 µM or 100 µM cystamine for 24 hours; then media was replaced with fresh 
media containing 18 µM cisplatin. Plates were subsequently incubated for another 24 hours, 
and cells harvested and prepared for flow cytometry analysis as described in section 2.5.    
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Figure 6.13: Apoptosis analysis of chemoresistant cells after TG2 inhibition by cystamine 
(a)  histogram of apoptosis analysis of resistant cells exposed to cisplatin after TG2 inhibition and (b) 
represents healthy cells amongst the groups. Significance is denoted by ** (0.0086), *** (0.0002) and 
**** (<0.0001), when analysed with the 2 way Anova. The results are computed from at least three 
independent experiments and presented as means ± SEM.  
 
 
 121 
 
Figure 6.13 shows that TG2-inhibited cisplatin-resistant cells were more sensitive to cisplatin 
than the cisplatin-resistant cells without TG2 inhibition. Viability of the chemoresistant cells 
was 70% after cisplatin treatment, but with TG2 inhibition, viability was reduced to 52% with 
50 µM cystamine and to 40% with 100 µM cystamine. 
6.12 Determination of TG2 enzyme activity  
 
The enzymatic activity following cystamine treatment in both wild type and cisplatin-resistant 
cell types was investigated with the TG2 COV assay kit. This was done by inhibiting TG2 with 
cystamine for 24 hours then media was replaced with fresh media and cells were incubated 
with the IC50 of cisplatin (18 µM for MCF-7 and 35 µM for RMCF) for a further 24 hours. Total 
protein was extracted, and the activity analysed, as described in section 2. 9.1. 
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Figure 6.14:  Enzyme activity of MCF-7 and RMCF after TG2 inhibition and cisplatin treatment. 
TG2 enzymatic activity determined using the TG2 COV assay kit of both wild type and cisplatin-resistant 
cells after TG2 inhibition. (a) Represents TG2 activity in the wild type cells; (b) depicts activity in the 
cisplatin-resistant cells while (c) compares TG2 activity between the wild type and cisplatin-resistant 
cell types. Statistical significance is symbolised by * (0.0305), ** (0.0087). when analysed with the 2 way 
Anova. The results are computed from at least three independent experiments and presented as means 
± SEM.  
 
 
 
Generally, from fig 6.14, cystamine treatment generated a minimal reduction of the enzyme 
activity in the wild type. In contrast, the enzymatic activity was slightly increased (by 20%) in 
the cisplatin-resistant cells.  
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6.13 Discussion  
The results generated in this chapter confirm previous reports about inhibiting TG2 activity 
with cystamine, and further reveal that TG2-L is more of the target isoform for inhibition than 
TG2-S. The inhibition of TG2 with cystamine reduced TG2-L levels substantially when 
compared to TG2-S (figure 6.8, figure 6.12), which led to the cells becoming sensitive to 
cisplatin at a reduced cisplatin dose (figures 6.6 and 6.11) than the initial inhibitory 
concentration of the drug. A limitation of this experiment is the inability to determine the activity 
of the different isomers with the assay kit. 
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Chapter 7: TG2 silencing: does the silencing of TG2 protein expression influence 
resistance reversal? 
 
7.1 Introduction  
Gene silencing is the art of ‘turning off’ a gene by machinery other than genetic mutation 
(Redberry, G.W., 2006). From the preceding chapter, inhibition with cystamine showed the 
effect of inhibiting the long-form of TG2 on cisplatin cytotoxicity. In this chapter, small 
interfering RNA (siRNA) was used to specifically knock-down TG2 to determine if knock-down 
produces similar results and which isoform will be silenced. 
7.2 Effect of lipofectamine on cell viability 
 
The viability of cells exposed to the transfection agent lipofectamine was tested, to rule out 
deleterious effects associated with using this vehicle for transfection. Cells were seeded in 96 
well plates and exposed to the concentration of lipofectamine for the transfection studies (0.3 
µl in 100 µl media), in the absence of siRNA. 
 
 
 
 
 
 
 
 
 
 
Figure 7.1: Viability of MCF-7 cells after lipofectamine treatment 
Cell viability of lipofectamine-treated cells and non-treated control cells was determined with the CCK-
8  assay. Results were computed from means of at least three independent experiments (±SEM), and 
the difference was not statistically significant when analysed with the student T-test. 
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Figure 7.1 shows that lipofectamine-treated cells are still fully viable at the concentration (0.3 
µl in 100 µl media) used for transfection, when compared to the control cells, indicating that 
the concentration of lipofectamine (Table 2.3) used for transfection was not harmful to cells. 
7.3 Flow cytometry analysis of cells treated with lipofectamine 
 
The analysis of cells by flow cytometry was performed to confirm the viability assay in figure 
7.1. 
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Figure 7.2:  Cytometry analysis of lipofectamine-treated cells  
Representative cytogram of cells treated with lipofectamine. (a) SSC-A/FSCA to collect single cells, (b) 
gating from excluding cell debris and doublets. Representative cytogram of control cells (c) MCF-7 
control cells, (d) lipofectamine treated cells (e) the histogram illustrated the difference between both 
groups and were not significant by the 2 way ANOVA test. Data was computed from the means of at 
least three independent experiments (±SEM). 
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Results from figure 7.2 support the MTT assay results (fig 7.1), confirming that the 
concentration of the transfection agent was not harmful to the cells, as over 80% of cells were 
still healthy after lipofectamine treatment.  After the confirmation that cells were not affected 
by the transfection vehicle, the process of transfecting with specific TG2 siRNA was then 
performed, as described in section 2.10. 
 
7.4 Characterization of MCF-7 cells after TG2 silencing 
 
Images of cells were taken before and after silencing to compare morphological differences 
between the treated and non treated cells. Cells were seeded in 6-well plates overnight to 
allow them to adhere and media was replaced with fresh media with the transfection reagent 
and TG2-specific siRNA, according to the manufacturer's protocol (see section 2.10) 
 
Figure 7.3: Morphology of MCF-7 cells transfected with specific TG2 siRNA 
Optical pictogram of (a) MCF-7 control cells (b) TG2-silenced MCF-7 cells. The images were 
photographed with the ZOE™ Fluorescent Cell Imager. The scale bar was set at 100 µM.  
 
 
From the image in figure 7.3, there were no significant morphological differences between the 
transfected cells and control.  
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7.5 Cell death analysis of cells after TG2 silencing by flow cytometry 
After transfection, cells were harvested and prepared for flow cytometry analysis as described 
in section 2.5 to determine the characteristics and state of cells. 
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Figure 7.4: Flow cytometry analysis of MCF-7 cells after siRNA transfection 
Cell death analysis of cells stained with Annexin V and propidium iodide after transfection. Cytogram of 
cells treated with lipofectamine. (a) SSC-A/FSC-A to collect single cells, (b) gating to exclude cell debris 
and doublets. Representative cytogram of control cells (c) represents the control, while figure (d) 
represents the transfected cells. The histogram (e) shows the populations of cells amongst the different 
groups. Results are computed from the means of at least three independent experiments (±SEM), and 
the differences were not statistically significant.   
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From figure 7.4, following treatment with TG2-specific siRNA, over 80% of cells in both cell 
groups were in the healthy state. This signifies that cells were still healthy after transfection 
and confirms that transfection was not detrimental to the healthy state of the cells.        
 
7.6 Determination of TG2 expression after transfection in wild type MCF-7 cells 
 
The expression of TG2 was determined following transfection. 1 x105 cells were seeded in a 
24-well plate and incubated overnight so cells could attach to plates. Following the protocol 
(section 2.8), media was then replaced with Opti-MEM medium containing transfection agent 
with specific anti-TG2 siRNA and incubated for 24 hours. Media was then replaced with fresh 
media for another 24 hours. At the end of the period, cells were harvested, and protein 
extracted for Western blotting (section 2.6 and 2.7).  
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Figure 7.5: Effect of silencing on TG2 levels in wild type MCF-7 cells 
Representative Western blot of TG2 levels in wild type MCF-7 cells after transfection (a), The 
histograms represent band quantification of TG2-L expression (b) and TG2-S expression (c). 
Normalisation was with β-actin, and results were computed from the mean from at least three 
independent experiments (±SEM), and significance is denoted by ** (0.0081)  when analysed with the 
2 way Anova. 
 
 
Overall, the blot in figure 7.5 shows that transfection was successful. Compared to the controls 
(W, LP and Neg), TG2-L was silenced more substantially while TG2-S expression seemed to 
be maintained. The differential expression of the isoform before and after TG2-specific 
silencing is shown in Table 7.1.  The negative control was used to validate the transfection 
process, but a reduction of TG2-L was noticeable.   
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Table 7.1: Isoform ratio in wild type MCF-7 cells  
Isoforms Ratio before silencing Ratio after silencing 
TG2-L: TG2-S 4:1 1:3 
 
7.7 Effect of transfection on wild type cells’ sensitivity to cisplatin  
After silencing TG2 in figure 7.5, the IC50 of cisplatin was determined, to compare with the 
inhibitory concentration obtained in figure 4.1. For this assay, cells were seeded in 96-well 
plates according to the protocol for transfection in section 2.8.  After cells adhered to the plate, 
the media was replaced with fresh media with a series of increasing concentrations of cisplatin, 
and the plate was incubated for 24 hours. Cell viability was determined with the CCK-8 assay 
(section 2.2.1). 
 
 
 
 
 
 
 
 
 
Figure 7.6: Cytotoxicity of cisplatin after transfection with ant-TG2 siRNA on wild type MCF-7 
cells. 
Cytotoxicity of cisplatin on transfected cells determined using the CCK-8 assay. and results were 
computed from the mean of at least three independent experiments (±SEM). Statistical significance is 
denoted by **** (<0.0001) and ** (0.0011).  
 
Figure 7.6 shows that the inhibitory concentration of the transfected cells was lower than that 
of the control cells. The IC50 of the wild type was 18 µM, but after silencing TG2-L, it was 
reduced to 6 µM, suggesting a relationship between TG2-L and sensitivity of the cells to 
cisplatin.  
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7.8 Determination of TG2 activity  
 
The activity before and after the knock-down was also determined by flow cytometry using 
labelled demonstrate (section 2.9.2).  2 x105 wild type MCF-7 cells were seeded into 24-well 
plates overnight to adhere to the plates. After 24 hours, media was replaced with media 
containing specific TG2 siRNA and incubated for a further 24 hours. Cells were prepared after 
transfection as described in section 2.9.2 for flow cytometry analysis. The relative fluorescent 
units (RFU) values were used as a measure of the activity of the enzyme. 
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Figure 7.7: Enzyme activity of TG2 siRNA transfected wild type cells 
TG2 Enzyme activity in wild type MCF-7 cells after transfection determined by flow cytometry. Cytogram 
(a) showing all events (b) gating to exclude cell debris and doublets (c) control MCF-7 cells (d) negative 
cells (e) transfected MCF-7 cells. The results were computed from the mean of at least three 
independent experiments (±SEM), and the difference was not statistically significant when analysed 
with the one-way ANOVA.  
  
The cisplatin-resistant cells were also transfected with specific TG2 siRNA for comparison with 
the wild type cells.  
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7.9 Apoptosis analysis of cisplatin-resistant cells after TG2 silencing by flow cytometry 
The state of the cells was assessed to ensure cells were healthy after transfection and cell 
death was due to the silencing of the TG2 gene.  
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Figure 7.8: Flow cytometry analysis of cisplatin-resistant cells after transfection with TG2 
specific siRNA 
Cell death analysis by flow cytometry after transfection. (a) SSC-A/FSCA to collect single cells, (b) 
gating to exclude cell debris and doublets. (a) representative cytogram of RMCF-7 control cells and (b) 
RMCF-7 cells after transfection with TG2 specific siRNA. The histogram (c) shows that the populations 
of cells amongst the different groups was not statistically significant when analysed with the 2 way 
Anova.  Data were computed from the mean of at least three independent experiments (±SEM).  
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Figure 7.8a characterises the RMCF-7 cells into the healthy, early apoptotic, late apoptotic 
and necrotic categories, while figure 7.8b shows the equivalent characterisation for RMCF-7 
cells treated with TG2 specific siRNA. Differences observed between the transfected cells and 
control was not significant.  This result confirms that the chemoresistant cells were still healthy 
following transfection with TG2 specific siRNA. 
7.10 Effect of silencing TG2 on the sensitivity of the cisplatin-resistant cells to cisplatin  
 
The sensitivity of the transfected cisplatin-resistant cells to cisplatin was also investigated.  
Briefly, cells were seeded in a 96-well plate, transfection was carried out (see section 2.8), 
and then cells were exposed to a series of increasing cisplatin concentrations (0-40 µM).  
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Figure 7.9: Cytotoxicity of cisplatin after transfection with TG2 specific siRNA on the resistant 
cells. 
Cytotoxicity of cisplatin on TG2 siRNA transfected resistant cells determined using the CCK-8 assay. 
Data were computed from the mean of at least three independent experiments (±SEM), and **** 
denotes significance (<0.0001) and *** (0.0002). 
 
 
 
The result from figure 7.9 shows the sensitivity of the chemoresistant cells to cisplatin after 
TG2 knockdown was significantly increased, and conforms to the pattern observed in the wild 
type cells (figure 7.6). The graph shows that the inhibitory concentration of the transfected 
cells was 5 µM, while the IC50 of the control was 35 µM. The same argument can be sustained 
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that the sensitivity of the cells to cisplatin could be due to the reduction of the TG2-L gene, 
which encourages cell survival.  
 
7.11 Determination of TG2 expression following gene silencing in cisplatin-resistant 
MCF-7 cells 
 
Cisplatin-resistant cells were seeded in 24-well plates and transfected with the same specific 
TG2 siRNA used in the wild type cells. Protein was extracted and TG2 expression determined 
by Western blotting.  
 
 
Figure 7.10: Effect of TG2 silencing on TG2 levels in cisplatin-resistant cells 
Representative Western blot of cisplatin-resistant cells after TG2 silencing (a), the histograms represent 
band quantification of TG2-L (b) and TG2-S (c). The results were computed from the mean of at least 
three independent experiments (±SEM), and significance is denoted *** (0.0005) when analysed with 
the 2-way Anova 
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The Western blot in figure 7.10 shows that transfection was also successful in the 
chemoresistant cell. A reduction was observed in TG2-L expression in the cells silenced with 
specific TG2 siRNA was noticed. Isoform analysis shows a significant difference between the 
reduction in TG2-L levels in the RMCF-7 control and the transfected cells, while the reduction 
in TG2-S levels was not significant. The reduction of the isoform ratio with and without TG2 
specific siRNA silencing is shown in Table 7.2. Knocking-down, a large percentage of the long-
form may have allowed the short form to exert its function, stimulating cell death, as seen in 
figure 7.9. 
 Table 7.2: Isoform ratio in cisplatin-resistant MCF-7 cells  
 
Isoforms Ratio without TG2 silencing Ratio with TG2 silencing 
TG2-L: TG2-S 1.2:1 1:3 
  
 
 
7.12 Determination of TG2 activity after TG2-silencing in the cisplatin-resistant cells  
 
The enzyme activity with and without TG2 knock-down was determined by flow cytometry, 
using labelled dansylcadaverine (section 2.29,2). Briefly, 2 x105 RMCF cells were seeded into 
24-well plates overnight to adhere to the plates. After 24 hours, media was replaced with 
media containing specific TG2-siRNA and cells were incubated for a further 24 hours.  Cells 
were prepared after transfection as described in section 2.7.2, for flow cytometry analysis. The 
relative fluorescent units (RFU) values were used as a measure of the activity of the enzyme.  
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Figure 7.11: TG2 enzyme activity in RMCF  
TG2 enzyme activity of transfected cells determined by flow cytometry in cisplatin-resistant cells. 
Cytogram (a) showing all events (b) gating to exclude cell debris and doublets (c) control RMCF-7 cells 
(d) negative control and (e) transfected RMCF-7 cells. Data were computed from the mean of at least 
three independent experiments. The results were computed from the mean of at least three independent 
experiments (±SEM), and the difference was not statistically significant when analysed with the one-
way ANOVA.  
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Figure 7.11 shows a reduction of enzyme activity after transfection with TG2.specific siRNA. 
This method is nonspecific and does not indicate the activity of TG2-L or TG2-S separately, 
but the total activity of the enzyme. The reduction of activity could be due to the knockdown of 
the long-form, leaving the short-form active in the cells.  
7.13 Conclusion  
Overall after transfection, there is a marked reduction of TG2-L compared to TG2-S, which 
tipped the scales in favour of apoptosis and cell death. Silencing of the TG2 gene has shown 
TG2-L knockdown sensitises cells to cisplatin at lower concentrations. The result validates the 
inference that the proportion of TG2-L in the cell dictates the function of the protein.  
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Chapter 8:Comparison of tissue transglutaminase levels in MCF-7 and HCC 1806 cells 
 
 
8.1 Introduction  
The results generated in this study have shown the roles played by the different isoforms with 
regards to cisplatin resistance. This chapter determines and compares the levels of TG2-L 
and TG2-S in MCF-7 cells with those in a triple-negative breast cancer cell line (HCC 1806).  
8.2 Determination of TG2 levels in MCF-7 and HCC 1806  
 
Protein was extracted from equal number of cells (5 x 105) grown in a 6-well plate, as described 
in section 2.6 and 50 µg of whole-cell lysate was then analysed for TG2 expression by Western 
blotting (section 2.7). 
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Figure 8.1: Comparison of TG2 levels in MCF-7 and HCC 1806 breast cancer cells.  
Representative Western blot of TG2 expression in MCF-7 and HCC 1806 cells, β-actin was used as the 
loading control and for normalisation (a). The histograms represent band quantification of (b) MCF-7 
cells, (c) HCC1806 cells and (d) compares TG2 expression between both cell lines. The results were 
computed from the mean of at least three independent experiments (±SEM), and significance is denoted 
by ****(<0.0001). 
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The Western blot in figure 8.1 generally reveals a characteristic difference in TG2 expression 
between the two different cell lines. The difference is observed in TG2-L levels, which are 
notably decreased in the HCC 1806 cells but increased in MCF-7 cells while TG2-S levels are 
similar in both cell lines.  
8.3 Determination of enzyme activity  
 
The activity of TG2 transamidation activity in the two cell lines was compared to determine the 
presence of a relationship between TG2 expression (figure 8.1) and activity. The activity was 
determined by flow cytometry using labelled dansylcadaverine (section 2.9.2). 5 x 105 cells 
were grown in a 6-well plate overnight to adhere to the plate after 24 hours media was replaced 
with fresh media containing labelled monodansylcardavarine for a further 24 hours. After 
incubation, cells were harvested for fluorescent detection by flow cytometry. The relative 
fluorescent units (RFU) value were used as a measure of the activity of the enzyme. 
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Figure 8.2: Enzymatic activity of MCF-7 and HCC 1806 cells. 
TG2 enzyme activity determined with fluorescent dansylcadaverine by flow cytometry. The results were 
computed from the mean of at least three independent experiments (±SEM), and significance is denoted 
by ****(<0.0001). 
 
The graph shows the increased activity of the enzyme in the MCF-7 cells when compared to 
the HCC 1806 cells which suggest that the functions of TG2-L in MCF-7 cells may be more 
profound than HCC 1806 cells. 
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8.3 Discussion  
 
Results from this chapter have shown for the first time that the HCC 1806 cells also express 
TG2 and also shows the differential expression levels of isoforms. In comparison with MCF-7 
cells, TG2-L levels in HCC 1806 is 50% less than that found in MCF-7 cells while TG2-S levels 
are higher in HCC 1805 than MCF-7 cells. Reduced TG2-L levels in HCC 1806 might make 
these cells more sensitive to chemotherapeutic drugs. Previous reports (Table 8.1) shows that 
HCC 1806 cells are sensitive to cisplatin at lower concentrations. 
Table 8.1: Different responses of triple-negative breast cancer cells to cisplatin. 
Triple-negative cell type IC50 Author 
HCC 1806 2.5 µM Volk-Draper,2012 
HCC 1806 0.56 µM Pendleton, 2014 
HCC 70 2.3 µM Heijink et al., 2019 
HCC 1937 2.2 µM Heijink et al., 2019 
HCC 38 3.6 µM Heijink et al., 2019 
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Chapter 9 Discussion and future work 
 
9.1 Introduction 
 
Cancer research scientists, in conjunction with pharmaceutical companies, have slowly 
progressed clinical therapies with the eventual hope of overcoming this group of specific 
diseases. There has been substantial progress, and many key molecular mechanisms that 
contribute to the underlying genesis of cancer cells have been substantially identified, leading 
to the development of several varieties of anti-cancer drugs that can specifically target 
molecular cancer biomarkers. Although these drugs have demonstrated some capacity and 
raised expectations of someday completely defeating cancer, the problem of 
chemotherapeutic resistance, however, is still a hurdle that has yet to be overcome. 
Cisplatin which was discovered in 1965 and referred to as the ‘penicillin of cancer’, has been 
extensively used in many aspects of chemotherapy (section 1.18.1). It can be described as a 
‘first-generation’ platinum drug that now falls into the category of chemotherapeutic drugs that 
have limited use owing to their ability to cause often rapid development of chemoresistance in 
patients. Apart from chemoresistance, another primary reason limiting the use of cisplatin is 
its toxicity, which includes: gastrotoxicity; ototoxicity; allergic reactions; and myelosuppression 
(Hartmann et al., 2003). Despite efforts over recent decades to reduce its toxicity, to date, 
these efforts have not been particularly successful (Manohar and Leung, 2018). 
Currently, although cisplatin alone has not proved to be a particularly effective treatment for 
hormone-positive (ER+ve) breast cancer, it has found utility in combination with other anti-
cancer drugs, particularly as adjuvant chemotherapy for the treatment of hormone negative 
(ER-ve) cancers (Goel et al., 2010; Koshy et al., 2010; Wahba et al., 2015), including 
metastatic breast cancer, locally advanced breast cancer and primary breast cancer (section 
1.18.1). It is often combined with other drugs such as gemcitabine (Heinemann, 2002; 
Heinemann et al., 2006), docetaxel (Vassilomanolakis et al., 2005; Cai et al., 2018), or 5-
Fluorouracil (Kim et al., 1993; Lekakis et al., 2012) to accomplish the maximum effect, but 
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chemoresistance is a perpetual challenge and remains a significant obstacle towards 
achieving this goal. 
Thus, cisplatin is a good powerful drug with many advantages but some serious 
disadvantages. It is readily available, relatively inexpensive and appears that it may be a 
suitable drug for repurposing in order to overcome the challenge of toxicity and 
chemoresistance. If this could be achieved, then it might conceivably bring cisplatin back to 
its place as the ‘penicillin of cancer’ and back into general use. 
9.2 Increased TG2 expression reflects chemoresistance in MCF-7 cells 
 
It is now well established that TG2 can exert opposing effects in cells (Section 1.10.1.), 
modulating both cell proliferation and apoptosis functions in neuroblastoma cells (Tee et al., 
2010) and fibroblast cells (Antonyak et al., 2006). Its overexpression is often associated with 
increased chemoresistance (Mehta, K., 1994), and this observation is consistent with the 
results of this study, which shows that the modulation of TG2 expression had a significant 
effect on ER+ve cells’ response to cisplatin. For example, while the IC50 of parental MCF-7 
cells to cisplatin was 18 µM (figure 4.1), induction of TG2 with retinoic acid resulted in cells 
that became more resistant to cisplatin (figures 5.6 and 5.7), similar responses being seen in 
the chemoresistant cells (figure 5.9) with IC50 levels rising higher than 35 µM(IC50 levels of 
resistant cells). Also, the inhibition of TG2 activity with cystamine reduced the IC50  from 18 
µM to 5 µM in the wild-type cells (figures 6.4, Table 6.1) and from 35 µMto 20 µMin the 
cisplatin-resistant cells (figure 6.11). However, it was not self-evident from these observations 
whether TG2-S and TG2-L isoforms increase or decrease their expression in parallel during 
these processes or whether there is differential expression of isoforms that contributes 
towards the overall gross TG2-associated chemoresistant effect. Thus, a major aim of this 
project was to investigate this question. 
 
 148 
 
9.3 TG2-L modulation and its effect on MCF-7 sensitivity to cisplatin 
 
The results of this study on breast cancer cells generally reflect the pattern of TG2 induction 
by RA as shown in earlier studies, using diverse cancer cell lines, including liver cancer 
(Meshram et al., 2017), cervical cancer and prostate cancer cells (Cho et al., 2016). 
Furthermore, the data from the current study demonstrate for the first time that the specific 
isoform induced by retinoic acid is predominantly the long form (TG2-L) and that this is often 
accompanied by a reduction of expression of the short isoform (TG2-S). Also, inhibition with 
cystamine and silencing with TG2-specific siRNA reduced TG2-L expression significantly 
more than that of TG2-S, causing cells to become more sensitive to cisplatin at lower 
concentrations (figure 6.5, figure 7.6). 
Although cisplatin therapy has not been particularly effective in the treatment of patients with 
hormone-positive breast cancer, the results on MCF-7 cell lines suggest that modulation of 
TG2 isoform levels might represent a new route to therapy. However, the picture may be 
somewhat more complicated than the simple scenario of reducing TG2-L levels in breast 
cancer cells in order to sensitise them to cisplatin therapy. 
9.4 TG2 levels relationship to patient survival is dependent on the hormone status of 
patients 
 
Recent results obtained within our local Cancer Research Group (CRG) that have analysed 
microarray biopsy samples obtained from 1,942 breast cancer patients (fig 9.1) shows that 
ER-ve patients expressing higher TG2 levels have a higher survival rate than ER+ patients 
expressing higher TG2 levels (Blows, 2019; unpublished personal communication). 
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Figure 9.1: Tissue microarrays of TG2 expression in breast cancer tumours. 
(a)Invasive breast tumour tissue displaying  (i) control (ii) weak (iii) moderate (iv) strong TG2 expression 
(b) Survival curves of patients with invasive breast tumours that do and do not express TG2 (c) Survival 
curves of patients with ER+ive invasive breast tumours  that do and do not express TG2  (d) Survival 
curves of patients with ER-ve invasive breast tumours  that do and do not express TG2. Red lines are 
TG2 positive and blue lines are TG2 negative (Fiona Blows, 2019 - personal communication). 
 
However, this histological analysis is not able to discriminate which isoform contribute to the 
observed effect, or why this might be relevant. 
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9.5 Oestrogen positive status increases chemoresistance in breast cancers 
 
ERα, a subtype of oestrogen receptor(section 1.2.1), plays an essential role in the sensitivity 
of breast cancer cells to chemotherapy (Borras et al., 1990; Teixerra et al.,1995; Lee et al., 
2005). Previous studies have shown that ERα+ve breast cancer is less sensitive to 
chemotherapy than ERα-ve breast cancer (Berry et al., 2006; Wang et al., 2009). This 
relationship between hormone positivity and chemoresistance is understandable because 
earlier studies have shown that oestrogen encourages proliferation and metastasis through 
ERα extranuclear signalling (Saha and Vadlamudi 2012)  by promoting mitogen-activated 
protein kinase (MAPK), protein kinase C pathways and phosphatidylinositol 3-kinase (PI3K) 
in the cytosol (Chakravarty et al., 2010) 
These signalling pathways mediate its oncogenic and metastasic effects in breast cancer 
(Saha and Vadlamudi 2012; Lipovka and Konhilas, 2016), and non-small lung cancer cells 
(Fan et al., 2017). The principal cause of death for breast cancer patients is not primarily 
cancer itself, but metastasis and formation of aggressive secondary cancers that are resistant 
to conventional cancer therapy (Fidler et al., 2007). Also, metastasis is associated with 
treatment failure that accompanies drug resistance (Qian et al.,2017).  
Like increased oestrogen receptor expression, increased TG2 expression has been shown to 
encourage metastasis (Chhabra et al., 2009; Kumar et al., 2010; Cellura et al.,2015; Tabolacci 
et al., 2019), and also demonstrated to be involved with fibronectin and integrins, which aids 
adhesion (Akimov et al., 2000; Balklava et al., 2002).  Seo et al. (2019) further demonstrated 
that increased TG2 levels induce epithelial-mesenchymal transition (EMT) by inhibiting miR-
205.  Particularly interesting, the TG2 gene has also been demonstrated to be regulated and 
induced by oestrogen and oestrogen receptors (Lally, 2010). Thus, the oestrogen/TG2 
promotion of metastasis is expected to be higher in ER+ve breast cancers than in ER-ve 
breast cancers, although hormone-negative cancers are, broadly speaking, more aggressive 
and have a poorer overall survival rate than hormone-positive cancers (Li et al., 2017), 
probably owing to the multiple problems of inadequate DNA repair. 
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9.6 TG2 expression increases patient survival in patients with ER-ve breast cancer 
 
By reference to the preceding section (section 9.5), the synergy between oestrogen receptor 
signalling and TG2 expression would be predicted to result in reduced or substantially reduced 
TG2 expression in hormone-negative cancers. The comparative Western blot analysis from 
the current study (figure 8.1) appears to confirm this and shows that the MCF-7 cell line 
(ER+ve) expresses higher TG2-L levels than the ER-ve HCC 1806 cell line. This observation 
would be consistent with lower rates of TG2-driven metastasis in hormone-negative cancers, 
although being a more aggressive form of cancer; other factors are expected to drive disease 
development. However, further explanation is needed in order to explain why increased levels 
of TG2 in ER-ve cancers might increase patient survival compared to low TG2/ER-ve patients.  
9.7 A possible mechanism  
 
One possible explanation of why increased TG2 levels might increase survival levels in ER-
ve patients may relate to TG2’s established involvement with fibronectin and integrins. The 
data from this study has demonstrated that the predominant isoform induced during RA-
mediated TG2 induction is TG2-L. Thus, elevated TG2-L levels in ER-ve breast cancer may 
promote cellular adhesion, where its crosslinking activity might ‘trap’ cells preventing cells from 
migrating to other organs. Reduced metastasis in ER-ve patients, thus is advantageous with 
increased survival outcomes. In contrast, ER+ve breast cancer patients with elevated TG2 
levels will be prone to metastasis more significantly than ER-ve breast cancer patients 
because the hormone oestrogen, encourages metastasis and also induces TG2 (figure 9.2). 
However, as TG2 also encourages adhesion, any contribution of increased TG2 adhesion to 
ER+ve patients cells might be reduced owing to the promotion of metastasis by oestrogen. 
Assuming the primary cancer were unable to break away from its primary location. 
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Figure 9.2: Schematic diagram comparing the promotion of metastasis in ER-ve and ER+ve breast 
cancer patients 
TG2-L promotes both metastasis, and cellular adhesion in ER+ve and ER-ve patients, but the presence 
of ERα increases metastasis in ER+ve patients.  
 
9.8 Proposed hypothesis 
 
Collating the data generated from this study and previous reports, the hypothetical model 
proposed here suggests that TG2-L and oestrogen activate the PI3k/Akt signalling pathways 
resulting in the inhibition of Ikβα (a cellular protein that inhibits NF-kβ by keeping it in an 
inactive state in the cytosol). Therefore, NF-kβ becomes unrestricted and migrates into the 
nucleus where it activates the expression of several genes involved in inflammation and cell 
survival, thus promoting resistance. Also, inhibition of TG2 enzyme activity with cystamine 
reduces TG2-L levels in the cytosol, which then results in the translocation of the membrane-
bound TG2-S into the cytoplasm to exert its apoptotic function by activating pro-apoptotic 
signals. This suggests a TG2-L-TG2-S equilibrium; a shift with the reduction of TG2-L may 
disrupt the normal equilibrium leading to the translocation of TG2-S into the cytoplasm. 
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Depending on its GTP-binding or transamidation activity, TG2-L can differentially promote 
cellular adhesion by interacting with ECM proteins (fibronectin and integrins) or promote 
metastasis by inducing EMT. The hypothetical model suggests that elevated TG2-L levels with 
both GTP-binding and transamidation activity interacts with fibronectin and integrins promoting 
adhesion of cells. In ER+ve breast cancer patients, the model suggests that the GTP-binding 
activity of TG2-L is promoted by oestrogen,  and increased TG2-L levels inhibit miR-205, which 
elevates ZEB1 protein, inducing EMT. Thus, the induction of EMT encourages the migration 
of cells. The lack of oestrogen receptors and oestrogen could be suggested to be responsible 
for the difference between the survival rates seen in ER+ve and ER-ve breast cancer.  
 
Figure 9.3: Schematic representation of the proposed role of TG2-L in mediating resistance, 
cellular adhesion and metastasis. 
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9.9 Future laboratory work: 
 
TG2 is known to be involved in chemoresistance, and this study has provided evidence that 
elevated TG2-L, and not TG2-S levels, contribute to the development of chemoresistance in 
an MCF-7 model. Also, unpublished work from our group on the hepatocellular carcinoma 
HepG2 cell line suggests that the cellular location of the TG2-L and TG2-S isoforms also 
appears to be linked with their functions. The proportion of TG2-L and TG2-S in the cytoplasm 
and membrane fraction is yet to be determined in MCF-7 cells. Such knowledge will clarify the 
roles of the isoforms in cellular migration and adhesion.  
As a part of future laboratory work,  
1. Cisplatin-resistant HCC1806 (ER-ve) cell lines will be developed, and their expression 
patterns of the TG2  isoforms will be compared with those seen in MCF-7 cell (ER+ve) 
lines following retinoic acid, cystamine, and siRNA treatments, as described in this 
thesis. 
2. With regard to the involvement of the isoforms in cellular migration and/or adhesion, 
the wound-healing assay (scratch assay) will be undertaken following parallel 
treatments described in 1. The result will provide evidence to show which TG2 isoform 
(s) are involved in the migration of cells.  
3. The proportions of TG2-L and TG2-S in the cytosol and membrane fractions will be 
determined in both wild-type and cisplatin-resistant MCF-7 (ER+ve) and HCC1806 
(ER-ve) cells following retinoic acid, cystamine, and siRNA treatment, as previously 
described in 1. The result will provide evidence of the location of the isoforms before 
and after the development of resistance, and whether TG2-S translocates from a 
membrane-associated pool into the cytoplasm in breast cancer cells after cisplatin 
treatment, inducing cell death by apoptosis such as is seen in the hepatocarcinoma 
model ( Meshram Dipak, 2019 -personal communication). 
4. Further histochemistry work on patient tissue biopsy samples using antibodies specific 
for TG-2-L and TG2-S will be undertaken. This will confirm whether one or both 
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isoforms of TG2 are elevated in ER-ve breast cancer patients with high survival rates. 
As the antibody used in the current study was not isoform-specific, new antibodies will 
need to be sourced for this work. 
5.  Further studies are also required to investigate the modulation of TG2 by oestrogen 
to determine its effects on TG2 isoform expression and cellular proliferation. This work 
will effectively require the repetition of the experiments in (1) following pre-treatment 
of cell lines with a biologically significant range of oestrogen concentrations. 
6. The levels of expression of P13K and NF-kβ will be tested by Western blot analysis 
to develop the current hypothesis concerning TG2’s control of cell death and 
metastasis in relation to chemoresistance. 
7. Comparing the inhibition pattern of cystamine with other specific TG2 inhibitors which 
are now commercially available would improve the quality of experimental data based 
on cystamine inhibition of the enzyme. 
8. Finally, TG2 crosslinking interaction analysis to investigate the phenomenon in both 
ER+ve and ER-ve cells may provide evidence on the survival outcome of breast 
cancer patients expressing increased TG2 levels.  
 
9.10 Conclusion 
 
Collectively, the results of this study demonstrate that induction of TG2-L by RA may contribute 
to the development of cisplatin chemoresistance, accompanied by a reduction of expression 
of TG2-S in an MCF-7 model system. Thus, TG2-L could potentially be a target for 
chemotherapeutic therapy aimed at reducing its levels in chemoresistant cells so that cisplatin 
may be used at lower less toxic dose,s and thus be used widely, once again as an effective 
and affordable anti-cancer compound.  
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Appendix 
 
TG2 substrates 
Substate  Location  
Acidic proline rich protein Extracellular; enamel 
pellicle in oral cavity 
Actin 
Beta tubulin 
Crystallin 
Ezrin-radixin-moesin (ERM)-binding phosphoprotein 50 
(EBP50) 
Filamin 1 
Rho protein kinase 2 
RhoA 
Spectrin 
Tau protein 
Troponin 
Vimentin 
Vitronectin 
Cytoskeleton 
Aldolase A 
Alpha-synuclein 
Bcr-Breakpoint cluster  
Region 
Betaine-homocysteine S methyltransferase 
Arginase I 
Angiocidin 
Annexin I   
Calpain 
Caspase-3 
Cathepsin D 
Collagen 
Dihydropyrimidinase -like 2 protein 
Cytosol 
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Dual leucine zipper bearing kinase(DLK) 
Elongation factor 1α 
Elongation factor 1ϒ 
Enolase 
Eukaryotic initiation factor 4F(eIF-4F) 
F-box only protein 
Fatty acid synthase 
Fatty acid synthase 
Fructose 1,6-bisphosphatase 
Galectin 3 
Glutathione S-transferase 
Glyceraldehyde-3-phosphate dehydrogenase 
Huntingtin protein 
Importin β1 subunit 
Myosin 
NF-kappa -B inhibitor α 
Parkin 
Phosphoglycerate dehydrogenase 
Phosphorylase kinase 
Plasminogen activator inhibitor-2 
Protein synthesis initiation factor 5A 
RAP-α-2 macroglobulin related protein 
T-complex protein 1ϵ subunit 
Thymosin beta 4 
Ubiquitin 
Valosin 
Alpha-lactalbumin 
Beta casein 
Extracellular; Milk 
Alpha-2  macroglobulin  
Receptor 
Annexin I   
C-CAM 
Plasma membrane 
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Cluster of differentiation 38 
EGF receptor 
Ephrin A 
Adrenocorticotropic hormone  
Alpha-2 plasmin inhibitor 
C1 esterase inhibitor 
Collagen 
Fibrinogen alpha chain 
Fibrinogen gamma chain 
Fibronectin 
Glucagon 
Insulin 
Lipoprotein A 
Midkine 
Extracellular; plasma 
Alpha-2-HS-glycoprotein 
Bone sialoprotein 
Osteonectin 
Osteopontin 
 
Extracellular; 
mineralised compartment of  
bone 
Alpha-ketoglutarate 
ATP synthase 
Dehydrogenase 
Heat shock protein 60 
Aconitase 
Cytochrome C 
Heat Shock Protein 7 
Heat shock protein 27 
Prohibitin 
Mitochondrial matrix 
Amyloid beta A4 peptide Extracellular; 
Cerebrospinal fluid 
Androgen receptor 
AT-rich interactive  
Nucleus 
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domain-containing  
protein-1A 
Ataxin-1 
Deoxyribonuclease ϒ 
Galectin 3 
Histones 
Lamin A, C 
Nuclease sensitive element-binding protein1 
Nucleophosmin 
Periphilin 
Retinoblastoma protein 
SP-1 transcription factor 
UV excision repair protein RAD23 homolog B 
Valosin 
VEGFR-2 
Vigilin 
Band 3 anion transport  
Protein 
Band 4.1 protein   
Erythrocyte 
Beta endorphin 
Calbindin 
Histatin 
Exendin 4 
Gliadoralin A 
Human clara -cell protein Ig kappa chain C region 
Plasminogen 
Substance P 
Uteroglobin 
Vasoactive intestinal peptide 
Extracellular; secreted 
Beta-2-microglobulin Cell surface   
Binding immunoglobulin protein Endoplasmic reticulum  
lumen 
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Clathrin heavy chain Intracellular; vesicle  
membrane 
Cyclic Thymosin beta 4 
Protein  kinase  C  delta type 
Cytoplasm 
Elafin Skin 
Gliadin Vacuole 
Insulin-like growth factor binding protein-1 
Insulin-like growth factor binding protein-3 
Inter-alpha -inhibitor 
Extracellular fluid 
 
 
 
 
 
 
 
 
 
 
 
 
 
